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Abstract 
The use of nandrolone (19-nortestosterone) to enhance racing performance in 
sports including horse racing is prohibited. The detection of 5a-estrane-3iS,Ha-diol, 
a major metabolite of nandrolone, in horse urine samples is regarded as the 
confirmation of nandrolone administration. The urine samples are first screened by 
a radioimmunoassay and positive samples are then analyzed by gas 
chromatography/mass spectrometry (GG/MS) for 5a:estrane-3"，17o!-diol. Colts' urine 
samples are not routinely tested by these procedures because both nandrolone and 5a-
estxane-3/3,17ce-diol are produced endogenously. The current method depends on the 
measurement of urinary 5oj-estrane-3j8,17Q:-diol to 5(10)-estrene-3jS, 17a-diol 
(estrane/estrene) ratio by GC/MS analysis. A ratio exceeding unity is indicative of 
nandrolone administration. The GC/MS procedure is time-consuming and therefore 
not the ideal method for screening large number of samples. 
The present work focuses on the development of an enzyme-linked 
immunosorbent assay (ELISA) method for measurement of the estrane/estrene ratio 
in a samples of colt's urine. Monoclonal antibodies against 5a-estrane-3jS, 17ce-diol 
were developed after an ELISA to detect antibodies against 5of-estrane-3j(3,17of-diol 
had been established using rabbit polyclonal antibodies. Two hybridomas which 
secrete anti-5a-estrane-3jS, 17a-diol monoclonal antibodies were developed following 
fusion of NS-1 myeloma cells and spleen cells from C57 mice immunized with 5a-
estrane-3jS-ol-carboxymethyloxime-sheep serum albumin. One of these, C1E7, is 
specific to 5a-estrane-3]S, 17a-diol, 5a-estrane-30-ol- 17-one (also a metabolite of 
ii 
nandrolone but present in a much lower amount) and 5a-estrane-3jS-ol-17-
carboxymethyloxime (not a naturally occurring substance). Cross reactivity with other 
structurally related steroids did not exceed 6 %. In hapten inhibition studies, the 
antibody recognized 5a-estrane-3/3,17of-diol at concentration as low as 1 ng/mL. The 
other monoclonal antibody, C3D10, expressed an irregular pattern of cross reaction 
with other steroids and recognized 5of-estrane-3iS, 17of-diol only down to 200 ng/mL. 
Monoclonal C1E7 antibody is far more sensitive and specific to 5a-estrane-3/3,17a-
diol than G3D10 as well as the rabbit polyclonal antibodies. 
C1E7 was used in an ELISA to determine the 5of-estrane-3i8,17a-diol level in 
urine samples from a nandrolone administered gelding by ELISA. The 5a-estrane-
3/3,17of-diol level were found to be 559±15 ng/mL after hydrolysis, and 526土13 
ng/mL without hydrolysis while GC/MS analysis gave a similar detection level of 
545 ±10 ng/mL. These results suggested that C1E7 is a useful antibody for measuring 
5a-estrane-3jS, 17a-diol in horse urine samples. It is also of interest to note that C1E7 
also recognizes the glucuronide of 5o;-estrane-3i8,17a-diol. This property may be 
helpful in the simplification of the current procedures used and in enabling the direct 
y measurement of 5a-estrane-3jS,17Q!-diol in urine samples. 
The ELISA based on C1E7 monoclonal antibody could provide an alternative 
means to screen nandrolone administration in geldings and fillies. It is expected that 
monoclonal antibodies against 5(10)-estrene-3i8,17a-diol could be raised by a similar 
method described in this study. On completion, an ELISA method to detect 5a-
estrane-3/S，17a-diol and 5(10)-estrene-3jS, 17of-diol using specific monoclonal 
iii 
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antibodies to these compounds would be a useful screening method in the detection 
of the estxane/estrene ratio in colts' urine prior to confirmatory analysis by GC/MS. 
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BSA Bovine serum albumin 
G-DME Complete Dulbecco's modifed Eagle's medium 
CMO Carboxymethyloxime 
CR % Cross reactive percentage 
D-PBS Dulbecco's phosphate buffered saline 
DME Dulbecco’s modifed Eagle's medium 
DMSO Dimethyl sulfoxide 
EaBSA 5<x-Estram部-ol-17-carboxymethyloxime-bovine 
serum albumin 
EaCMO 5oL-Estrane-3^-ol-l 7-carboxymethyloxime 
EaOVA 5 a-Estrane-3p-ol-l 7-carboxymethyloxime-
ovalbumin 
EaSSA 5a-Estrane-3^-ol-l 7-carboxymethyloxime-sheep 
serum albumin 
ELISA Enzyme-linked immunosorbent assay 
FBS Fetal bovine serum 
FCA Freundfs complete adjuvant 
FIA Freund *s incomplete adjuvant 
GC/MS Gas chromatography/mass spectrometry 
HAT Hypoxanthine/aminopterin/thymidine 
HT Hypoxanthine/thymidine 
IC50 Concentration at 50 % inhibition 
IgG Immunoglobulin G 
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MOX Methoxyamine (2 %) in pyridine 




PBS-Tween Phosphate buffered saline with Tween 20 
PEG Polyethylene glycol 
RIA Radioimmunoassay 




1.1 Drug Abuse in Sport 
One of the problems associated with sport in modern times is the use of drugs 
to enhance performance in various sports competitions. The word "dope" has been 
adapted internationally to describe the problem and it means something that is 
"stimulating" (Oxford Dictionary). Doping appears to have come into common use 
at the beginning of the 20th Century and has increased with the development of the 
pharmaceutical industry. However, doping is not new can be dated back to the 
Olympics of ancient Greek (Moss and Cowan, 1986). None of the governing bodies 
in sport has explicitly defined doping, despite banning the practice. Many horseracing 
authorities classify a dope by its pharmacological action (Table 1.1). Detection of any 
of the listed drugs or their metabolites in a sample of body fluid from a racehorse 
would constitute an offence. A list of prohibited substances is used internationally by 
many racing organizations, the intention being to ban the use of any of these drug in 
斤 7 racehorses at the time of competition to ensure the fairness. 
Detection of doping in horses is performed by analyzing biological fluids, 
usually urine samples. The collection of urine is non-invasive and the quantities 
obtained are sufficient for such analysis. The drugs or their metabolites would tend 
to be present in relatively high concentrations soon after doping has taken place. In 
addition, urine is generally free of proteins and lipids. Extraction of those drugs or 
. : . . 1 . : . . 
Table 1.1. Prohibited substances under the rules of horse racing (Moss and 
Cowan, 1986). 
Drugs which act on the autonomic system 
the cardiovascular system 
the central nervous system 
Drugs which affect the coagulation of blood 
the gastxo-intestinal function 
the immune system and its responses 
Analgesics, antipyretic and anti-inflammatory drugs 
Antibiotics, synthetic antibacterial and antiviral drugs 
Antihistamines 
Antimalarial and other antiparasitic agents 
Cytotoxic substances 
Diuretics 




Sex hormones, anabolic steroids and corticosteroids 
2 
» . ” 
their metabolites in urine can be easily performed. The disadvantage is that the drug 
may be present as metabolites or in conjugated forms and the parent drug may be 
present only in a relatively low concentration. Hence direct detection of the drug may 
not be possible. Detection in blood is an alternative although the collection of blood 
samples is invasive and much less convenient. The drug concentration in blood is 
more easily interpreted than that in urine, and certain drugs which are not excreted 
in urine in detectable quantities can be detected in blood, for example, reserpine 
(Moss and Cowan, 1986). 
1.2 Drug Detection Methods 
Drug detection methods are important in the field of dope detection as well as 
in medicine and the biological sciences, such as drug development and forensic 
toxicology (Chamberlain, 1985). the various methods for drug analysis can be divided 
into four main categories. They include spectroscopy and fluorometry, 
chromatography, immunoassays and bioassays. 
1.2.1 Spectroscopic and Fluorometric Method 
These methods assume that the amount of light absorbed or emitted from the 
sample is a function of the concentration of the particular chemical under investigation 
in the sample. For a particular substance, a wavelength with maximum absorption 
could be found and this specific wavelength absorption, according to Bouguer-
Lambert-:Beer principles (Chamberlain, 1985), is proportional to the concentration of 
. 3 
. , , . : . .• .: ‘ .‘ .， 身. . 
that absorbing species. This idea provides a qualitative and also quantitative means 
in the analysis of that species in the sample and is known as spectrophotometry. 
Fluorescence occurs as a result of the absorption of light by drug molecules. The 
emitted wavelength is always a longer one than that of the absorbed light. Thus, in 
standard fluorescence assays, the sample is excited at one selected wavelength and the 
intensity at the second appropriate wavelength is measured. Because of the ability to 
select two separate wavelengths, the method has higher specificity than the absorptive 
method. Unfortunately, few drugs exhibit fluorescence, examples being frusemide 
(Haussler and Hajda, 1964) and propranolol (Capomacchia and Vallner, 1980). Non-
fluorescent species may be assayed, after transformation of the drug to a fluorescent 
derivative by either direct chemical action or by coupling with appropriate coupling 
agents. In contrast to the absorbance method, fluorimetry relies in the final 
measurement not on the transmitted light but on the emitted light at right angles to 
the incident light. Hence, the sensitivity of the fluorimetric method is better than the 
absorptive method due to lower background interference. 
1.2.2 Chromatographic Method 
Today, the most common method of drug analysis in biological fluids, 
undoubtedly, is chromatography which can be considered as a combination of a 
powerful separation step with a sensitive and specific detection system. The basic 
principle underlying all types of chromatography is that the system consists of two 
components, one stationary and one mobile phases. The rate at which the individual 
components in the mobile phase move down the stationary phase depends on their 
.4 
relative affinities for the two phases and this is the property which influences the 
required separation. Nowadays, in most analytical and clinical laboratories, 
chromatographic analysis is mostly done by one of two methods, namely, gas 
chromatography (GC) and high performance liquid chromatography (HPLC). 
1.2.2.1 Gas Chromatography (GC) 
In GC, the compounds to be separated are partitioned between a stationary 
phase, usually a high boiling point liquid coated onto an inert support and the gaseous 
carrier. Factors affecting separation include the temperature of the column, flow rate 
of the carrier gas and the nature of the stationary phase. The great advantage of GC 
is the fact that the gases emerging from the column can be monitored with great 
sensitivity using a variety of universal and specific detectors (such as, flame 
ionization detector, electron capture detector, nitrogen-specific detector and mass 
spectrometer). Although apparently an expensive mode of detection, the mass 
spectrometer (MS) as a GC detector is very extensively used (simply known as 
GC/MS). In MS, under high vacuum, an electron beam ionizes each compound 
and/or cleaves it into ionized fragments. A complex system of focusing devices 
separtes ions according to their mass and propel them to a detector that measures the 
abundance of each ion. A compound always breaks into the same fragment ions, so 
that a graph of the relative abundance of the ions versus their mass, known as mass 
spectrum, specifically identifies each compound separated by GC. The detector can 
be made extremely specific by the choice of the monitored ions. However, GC is 
limited to those compounds that can be vaporized at reasonable temperatures without 
. 5 
decomposition. 
1.2.2.2 High Performance Liquid Chromatography (HPLC) 
For high efficient separation, the particles of the stationary solid phase should 
be as small as possible. However, this reduction in particle size for higher efficiency 
would lead to an increase in the resistance to the flow of solvent, and this in turn 
means higher pressure is required to overcome this resistance. Hence, HPLC is a 
combination of highly efficient separation column, a constant solvent flow/pressure 
(created by a pump) together with a sensitive detecting system (ultraviolet (UV), 
fluorescence and MS). 
1.2.3 Immunoassays 
Immunoassay depends on the specific immuno-reaction between antibody and 
antigen. The use of immunoassay as a drug detection tool in biological fluids can be 
traced back to 1959 (Yalow and Berson, 1959), when insulin was detected in human 
plasma. An anti-human insulin antiserum was raised in rabbit. It has been shown that 
the addition of increasing amount of insulin to a mixture containing a fixed amount 
of antiserum (in excess) and radiolabelled antigen (insulin as tracer) caused a gradual 
decrease in the amount of tracer which was bound to the antibody. In addition, the 
binding of labelled antigen was found to have a quantitative relationship to the amount 
of unlabelled antigen present when the concentrations of antibody and labelled antigen 
in the reaction mixture were kept constant. This is the earliest report of 
. 6 . 
radioimmunoassay (RIA) which formed the basis for the development of various kinds 
of immunoassays. A schematic diagram of insulin RIA methodology is shown in 
Figure 1.1. Since its introduction, RIA has played an important role in facilitating and 
accelerating basic discoveries in biomedical sciences and has become a standard tool 
in laboratory medicine. The disadvantages of using radioisotopes have led researchers 
to developed appropriate non-radioactive substitutes. A number of non-isotopic labels 
have been used. They include bacteriophages (Haimovich and Sela, 1969)，free 
radicals (Leute ^ al., 1972), fluorescent groups (Soini and Hemmila, 1979)， 
chemiluminescent and bioluminescent groups (Simpson et al, 1979; Kricka and 
Carter, 1982), red blood cells (Adler and Lice, 1971), electron dense materials 
(Singer and Schick, 1961; Leuvering et al, 1980)，liposomes (Chan et al, 1978; 
Litchfield et ^/.,1984), metals (Gais et al, 1977) and enzymes (Ngo and Lenhoff, 
1982). Enzyme labelled immunoassays became more popular than other labelling 
�materials and gained a comparable reputation with RIA in analytical sense. Further 
studies on enzyme labelled immunoassay focused mainly on the development of 
separation free procedures which is known as enzyme-linked immunosorbent assay 
(ELISA) (Engvall and Perlmann, 1971; Van Weeman and Schuurs, 1971). The 
method is based on the physical immobilization of soluble antigens or antibodies to 
an insoluble solid phase in a way that all reacted immunological components were 
retained. After appropriate washing steps, the enzymatic reaction could occur in situ 
(without separation) which has a quantitative relationship with the antigens or 
antibody amount. 
.7 
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Figure 1.1. The radioimmunoassay (RIA) for insulin (Yalow and Berson, 
1959). The anti-insulin antiserum is incubated with the test 
sample and a fixed amount of radiolabelled insulin. After 
incubation, the bounded and unbounded fractions are separated 
by physical means. The amount of unlabelled insulin in the test 
sample will be inversely proportional to the radioactivity of the 
/ bounded fraction. 
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1.2.4 Bioassays 
Bioassay is a long established method employed by pharmacologists. It 
analyses drugs by observing or measuring the response of living specimens to the 
drugs. The living specimen could be a microorganism, a whole animal such as mouse 
or just a piece of gut tissue. Microorganism assay for analysis of antibiotics is a 
classic example. Antibiotics inhibit the growth of susceptible microorganisms which 
are inoculated and incubated in a suitable nutrient medium. The antibiotic samples 
I 
under testing are spotted onto a uniform layer of the nutrient medium seeded with the 
sensitive microorganism. After incubation, there is a inhibition zone of growth of the 
microorganism (response to the drug) around the spot, the diameter of this zone will 
be related to the concentration of the antibiotics spotted. The bacterium Escherichia 
coli has been used for the specific detection of the antibiotic cefotaxime (White et al， 
1980). 
1.2.5 Analytical Methods for Detection of Doping 
In choosing a suitable analytical method for a drug of abuse in biological 
fluids, the initial consideration should be the purpose of the analysis. The purpose 
could be a qualitative identification of the drug from a large number of samples 
(screening) or a confirmatory evidence for doping. This concerns with the practicality 
of the method. A procedure involving extraction, purification and derivatization of 
the samples before actual analysis would be impractical for mass screening purposes. 
The expense for carrying out the analysis should be correlated to analytical value 
.9 
obtained in a sense of cost-effectiveness. If accuracy of the analysis is the main 
concern, the specificity as well as the sensitivity of the method must be the core 
subjects of discussion. Moreover, the speed by which such analysis is carried out 
should also be considered. Automation could greatly improve the speed of the 
analysis. A broad comparison of four main categories of analytical method on 
practicality, specificity, sensitivity, cost, time consumption and the possibility of 
automation is given in Table 1.2. 
For doping purpose, the drug is generally administrated at its effective 
concentration, which means a relatively low concentration in biological fluids (ranging 
from ng/mL to pg/mL is common). Therefore, the analytical method must be 
sensitive enough to detect the drug or its metabolites at such a low concentration. The 
assay should also be specific enough to detect only the drug or it metabolites. Some 
drugs used in doping are endogenous substances, for example, steroids; others may 
be part of the diet, for example, caffeine in beverages. Only when one of these drugs 
exceeds a certain pre-determined level could doping be confirmed. Chromatography 
and immunoassay generally have the sensitivity and specificity for drug detection 
although both methods have their disadvantages. Chromatography, especially GC/MS, 
is the most accurate method. However, it usually requires work-up procedures, such 
as extraction, before the samples are analyzed. It is a time-consuming method if a lot 
of samples are involved. On the other hand, the immunoassays provide a specific 
detection, but very often requires the drug or its metabolites be chemically well 
defined. Therefore, immunoassay could not be used as a final confirmatory method. 
It would be ideal to use an initial screening method such as immunoassays, and 
. 10 . 
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Table 1.2. A comparison between different categories of drug analysis methods 
with respect to their practicality, specificity, sensitivity, time 
consumption, cost and the possibility of automation. 
Spectroscopic Chromatography Immunoassay Biological 




Practicality Simple Complicated Simple Complicated 
Specificity Broad High High Broad 
Sensitivity pg-mg/ml pg-mg/ml pg-^g/ml pg-mg/ml 
Cost Low High Low High 
Time-Consumption Low High Low High 
Automation Possible Possible Possible Difficult 
11 :. 
subsequent positives in screening are reconfirmed by chromatography method, such 
as GC/MS or HPLC (Wadler and Hainline, 1989). The overall analysis system would 
be faster and more cost-effective. Such testing methods are well established in the 
analysis of amphetamines, benzodiazepines, cocaine and other opiates in athletes 
(Hoyt>r a/., 1987). 
1.3 Doping with Anabolic Steroids 
Anabolic steroids are synthetic derivatives of the natural male sex hormone 
testosterone (Figure 1.2). They are better known as "anabolic-androgenic steroids", 
as they produce both anabolic (tissue-building) and androgenic (masculinizing) effects. 
Pharmaceutical development of anabolic steroids has been directed towards the 
production of synthetic analogues which maintain the anabolising properties at the 
expense of the androgenic effects, as well as improvements in their pharmacokinetic 
properties. This has led to three principal chemical modifications of the testosterone 
molecule. Firstly, esterification of the 17jS-hydroxyl group with a variety of 
carboxylic acids to increase lipid solubility, allowing for the development of slow-
releasing injections. Secondly, alkylation at the 17a position would decrease the first 
pass metabolism in the liver, hence, increasing the bioavailability of the drugs. 
Thirdly, the demethylation at C6 position extensively reduces the androgenic effects. 
Figure 1.2 illustrates the chemical modifications on testosterone yielding persistent, 
orally active and non-androgenic analogues. The mechanism of action of anabolic 
steroids is the same of those endogenous steroids, like corticosteroids. In 1977, the 
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Figure 1.2. Three major structural modifications of testosterone yielding 
non-androgenic, more persistent and orally active synthetic 
anabolic steroid analogues. 
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understanding of steroid action at the molecular level. Steroids penetrate freely into 
cytoplasm where they bind to the specific protein receptors. The steroid-receptor 
complex is translocated to nucleus resulting in activation or deactivation of genome, 
hence, increasing or decreasing the transcription of certain genes, thus, bringing about 
the biological actions of steroids (Munck and Leung, 1977). In addition, the 
biological effects of synthetic anabolic steroids resemble those of testosterone 
(Wilson, 1991). 
Anabolic steroids have proven beneficial, both in medical and veterinary 
practice for stimulation of a positive nitrogen balance (Beroza, 1981). The steroids 
became available to physicians following World War II and were used in attempts to 
speed recovery from starvation and major surgery. Currently, anabolic steroids are 
used therapeutically for testosterone deficiency in males, anaemia due to failure of 
bone marrow and hereditary angioneurotic oedema (Wilson and Griffin, 1980). In 
1954, the Russians were reported to be the first to use anabolic steroids to improve 
the performance of athletes followed by the Americans and others (Wade, 1972). 
Initially, these drugs were used in sports requiring great strength or muscular size, 
such as weight lifting, short putting and body building. Later, other athletes have 
been tested positive for anabolic steroids in sprint and distance running, wrestling, 
swimming and all other fields of human sports (Shuer, 1982). In the veterinary field, 
anabolic steroids may be valuable in conditions associated with a high rate of tissue 
breakdown or in cases of post-operative convalescence (Brander and Pugh, 1971). It 
has been showed that 1-dehydrotestosterone undecylenate improved the condition of 
debilitated horses and increased their weight gain and endurance positively (Stihl, 
1968) v Desirable haematological effects in the above study was also notable. 
However, later studies concluded that there was no clear-cut improvement in 
performance of racehorses after monthly injection of nandrolone decanoate with a 
regular training schedule, nor any significant haematological effect (Dietz et al, 
1974). Despite the conflicting results, some trainers and horsemen still gave anabolic 
steroids to their horses in order to gain advantages in competitions. Some of the 
anabolic steroids used in athletes and racehorses are listed in Table 1.3. Owing to 
their well documented toxic effects on the liver, lipid metabolism and the 
cardiovascular system (Haupt and Rovere, 1984; Hickson et al，1989; Grahram and 
Kennedy; 1990), anabolic steroids are both prohibited by the authorities governing 
human sports and horseracing. As a consequence, many procedures for detection of 
different kinds of anabolic steroids administration have been developed in both the 
human and veterinary fields/Basically, the procedures involve a mass screening by 
immunoassay and a final confirmation by chromatographic method. 
1.4 Abuse of Nandrolone in Racehorses 
The racing rules of the Royal Hong Kong Jockey Club (RHKJC) prohibit the 
use of any drug at the time of competition. Considerable efforts have been made to 
detect and control the abuse of anabolic steroids because of their adverse effects. The 
( 
abuse of anabolic steroids in horseracing dates from the early 1970's. The steroid 
which gained the most nototiety in this field is nandrolone (19-nortestosterone). It is 
a 6-demethylated derivatives of the natural sex steroid testosterone. The demethylation 
at C6 position greatly reduces the androgenic effects and retains most of the anabolic 
. • 15 .. 
Table 1.3. Commonly used Anabolic Steroids in Human Sports and Horse Racing. 
Generic Name Trade Name 









Injectable anabolic steroids 
stenobolone Anatrofin 
testosterone nicotinate Bolfortan 
nandrolone decanoate Deca-Durabolin 
testosterone enanthate Delatestryl 
testosterone cypionate Depo-Testosterone 
methandrostenolone Dianabol 
nandrolone phenpropionate Durabolin 
hexoxymestrolum Enoltestovis 
boldenone .. Equipoise 
methenolone enanthate Primobolan 
a mixture of testosterone esters Sustanon 250 
Therobolin 
Trophobolene 
stenozolol Wintrol V 
.16 
effects of testosterone. It is administrated intramuscularly to horses as the 
phenylpropionate ester (Nandrolin or Durabolin) or laurate ester (Laurabolin) in 
arachis oil (Figure 1.3). 
In the early 1970's, nandrolone was commonly used in horseracing, as 
methods of detection or identification of the drug in horses were not available. At this 
time, the Horseracing Forensic Laboratory and the Racecourse Security Services 
Laboratories in United Kingdom took up the responsibility to develop a suitable 
procedure for screening and identifying the horse urinary products resulting from 
nandrolone administration. Two separate approaches were used. Firstly, the RIA 
procedure was explored as a possible screening test which could handle large number 
of samples in a cost-effective and rapid way to discriminate between the negative 
samples and the handful of positive ones. Secondly, studies were undertaken into the 
metabolism and urinary excretion of nandrolone in horses with a view to developing 
a confirmatory analysis procedure based on GC/MS. 
1.4.1 RIA for Nandrolone 
RIA for steroid detection is a long established method and can be dated back 
to the late 1960，s. In the mid-1970，s, RIAs for anabolic steroids were first used to 
detect the use of the drugs in athletes attending various international sport 
competitions (Sumner, 1974; Brooks et al., 1975). In horseracing, methods for 






Figure 1.3. Structures of nandrolone and its esters Nandrolin 
� (R=COCH2CH2(C6H5)) and Laurabolin (R=CO(CH2)10CH3). 
18 
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It has been mentioned that substances with a molecular size smaller than 5,000 
are not immunogenic (Catty and Raykundalia, 1988). This also applies to nandrolone 
which has a molecular weight of 274. In order to develop an antibody against 
nandrolone, it was covalently linked to a protein carrier. Nandrolone contains 
hydroxyl and keto groups which cannot be used efficiently to form strong covalent 
bonds with the protein. Peptide bonds are among the most stable and various 
approaches have been described to form peptide bonds between steroids and the 
carrier (Lieberman et aL, 1959; Thorneycroft et a/., 1970; Goodfriend and Sehon, 
1970). According to the method of Abraham and Grover (1971)，a nandrolone-protein 
conjugate has been synthesized for raising antibodies in animals (Jondorf, 1977), The 
keto group at C3 position was converted to a carboxymethyloxime group which has 
a carboxylic acid group ready for peptide bond formation with the amino group of the 
lysine residues on bovine serum albumin. The conjugate known as nandrolone-3-
carboxymethyloxime-bovine serum albumin was synthesised and used to immunize 
Soay ewes using Freund's adjuvants. As a result, an antiserum against nandrolone, 
which was designated as V-2711, was obtained. V-2711 was then subjected to cross-
reactivity studies by incubating a number of unlabelled potential cross-reacting 
steroids together with 3H-nandrolone in RIA determination. Results indicated that the 
antiserum cross reacted to those steroids possessing a 17/3-OH group which was 
believed to be the antigenic recognition site. The endogenous steroids testosterone and 
dehydrotestosterone showed the highest cross reactivities with the antiserum which 
are 23.0 % and 26.3 % respectively. Based on V-2711 antiserum, a practical RIA 
screening procedure for the determination of nandrolone levels in horse urine samples 
was developed (Jondorf and Macdougall, 1977; Jondorf and Moss, 1978). 
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1.4.2 Metabolism of Nandrolone in Horses 
The initial studies on the metabolism of nandrolone in horses was carried out 
by Houghton (1977). The metabolism was studied in cross-bred horses using Re-
labelled materials. Two neutral urinary metabolites have been identified, the 17-oxo 
steroid and estxane-3,17-diol. 
o /O H 
17-oxo steroid estrane-3,17-diol 
Both of them were in conjugated forms and could only be extracted after enzymatic 
hydrolysis. In this respect, the metabolism of nandrolone in horses resembles that in 
rabbits (Both-Miedena et al., 1972). The conversion of nandrolone into the 17-oxo 
steroid has also been reported in man (Dimick et al, 1961; Ward et al, 1975). An 
investigation into the stereochemistry of these two metabolites revealed that the 17-
oxo metabolite has the 3jS-0H configuration and the estrane-3,17-diol has a 17a-0H 
configuration. Since the nandrolone has a 17/3-OH configuration, the diol has 
undergone epimerization during metabolic processes. Insight from the studies of 
testosterone in man and other animals suggested that nandrolone is metabolized in part 
to an estrane-3,17-diol either via direct epimerization or through a 17-oxo 
intermediate. The research community then focused on this major metabolite and a 
GC/MS method for estxane-3,17-diol determination in horse urine was developed 
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(Houghton et al., 1978). This GG/MS quantification for the steroid became a 
confirmatory tool for nandrolone administration in horses at that time. Further studies 
using the similar radio-labelling techniques demonstrated there are some other urinary 
metabolites are excreted besides the two mentioned above (Houghton and Dumasia, 
1980). They are nandrolone with 17/3-OH and 17a-OH configuration in addition to 
some minor 16-oxygenated metabolites. In common with other mammalian species, 
horses show a biphasic pattern of steroid metabolism (Dumasia and Houghton, 1984). 
The metabolic pathway of nandrolone was finally reconstructed as follows (Figure 
1.4). Firstly, the phase I biotransformation of nandrolone can be summarized as the 
reduction of A4-3-OXO group in the A-ring, epimerization of hydroxyl group at the VW 
position to the 17a epimer, oxidation at C17 position with the formation of 17-oxo 
compound and oxygenation at C16 position. The stereochemistry of hydro and 
hydroxyl* groups on the estrane-3,17-diol A-ring were found to be in 5a and 3/3 
configuration respectively. Secondly, the phase II biotransformation of nandrolone is 
the formation of glucuronides and sulphoconjugates of those metabolites; the 
metabolites with a 17QJ-OH group are selectively conjugated to glucuronic acid and 
the Y7/3 isomers with sulphate. It was believed that both nandrolone and 5a-estrane-
3iS,17a-diol were not present urine from normal horses. These studies established a 
rather detailed picture of nandrolone metabolism in horses and considered 5o;-estxane-
3/3,17a-diol glucuronide as the major urinary metabolite for confirmatory analysis. 
1.4.3 Procedures for Detection of Nandrolone Administration in Horses 
Based on these studies, a comprehensive test for nandrolone was formulated. 
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Figure 1.4. The proposed mechanism for nandrolone metabolism in 
� horses (Dumasia and Houghton, 1984). See text for 
explanation. 
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The urine samples were first mass screened by RIA for nandrolone. It was known 
that urine sulphate conjugates would not be hydrolysed by the mixed digestive enzyme 
from sn^l Helix pomatia (Houghton and Dumasia, 1979)，but could be broken down 
by mild acid hydrolysis or known as solvolysis (Thacker et al，1984). This procedure 
releases more nandrolone from the sulphate fraction and greatly enhances the 
sensitivity of the RIA screening. Positive samples were subjected to a confirmatory 
test by GC/MS for the presence of 5a-estrane-3]S，17a-diol and together these two 
findings constituted a positive case. Untreated geldings and fillies were almost 
negative to RIA test, but colts (sexually mature male horses) frequently presented a 
problem because of the endogenous testosterone which cross-reacted with the 
antibody. As a result, colt samples could only be tested by the GC/MS method at this 
stage. 
1.4.4 Vayrann Case 
In 1981, a three-year old colt Vayrann, owned by the Aga Khan, won the 
Champion Stakes at Newmarket, United Kingdom. Urine from this horse was 
analyzed by GC/MS and found to be 5a-estrane-3/3,17a-diol positive. Thus, on the 
basis of the evidence and knowledge prevailing at that time, the sample was declared 
positive for the administration of the anabolic steroid nandrolone. During subsequent 
investigations leading up to an enquiry in this case, it was observed by the staff of the 
Racecourse Security Services Laboratories that 5of-estrane-3iS，17a-diol and nandrolone 
in fact could be detected as trace components in normal urine from some sexually 
matured colts (Houghton et al，1984), As a result, the horse finally retained the prize 
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money following the enquiry. It soon became apparent that thepresence of these C-18 
steroids was an age-dependent event, first appearing around the age of three years. 
The explanation for the failure to find the steroids previously is that horses generally 
start their racing career as two-year olds (Houghton et al，1984). 
1.4.5 Detection of Nandrolone Administration in Colts 
The Vayrann case presents two challenging questions to those horseracing 
analysts. Firstly, how could administration of nandrolone be detected in a horse 
already producing the two steroids. Secondly, by what biochemical pathway were the 
two steroids formed endogenously . After several investigations on colts of different 
ages using radio-labelling techniques and GC/MS, a further C-18 steroid, closely 
related to 5a-estrane-3/5,17cx-diol was found in normal colt's urine. It is the 
unsaturated counterpart of 5a-estrane-3"，17a-diol known as 5(10)-estrene-3,17-diol 
(Houghton et al., 1984). 
OH 
5(10)-estrene-3,17-diol 
This steroid is not a metabolite of nandrolone. GC/MS comparison of the urinary 
steroid profile in colts showed that the ratio of 5of-estrane-3i5,17a-diol to 5(10)-
estrene-3,17-diol is less than unity (Houghton et al” 1985). If nandrolone is given, 
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the ratio of this two steroids might be altered. Since 5a-estrane-3/3,17a-diol, but not 
5(10)-estrene-3,17-diol, is a metabolite of nandrolone, such an alteration in the steroid 
ratio may provide a reliable diagnosis for nandrolone administration in colts. 
The production of these C-18 steroids, nandrolone, 5a-estrane-30,17a-diol and 
5(10)-estrene-3,17-diol was later explained by Smith et al (1987). They isolated 
steroid products after incubation of a mixture of radiolabeled steroid substrates with 
horse testicular tissue. According to their findings, a proposed mechanism for the 
formation was set up (Figure 1.5) . The initial step is the hydroxylation of testosterone 
at C19 position. Deformylation of the 19-hydroxysteroid via a reverse aldol-type 
condensation yields an intermediate. Protonation of this intermediate at one of the two 
sites can yield either a A4-3-oxosteroid (nandrolone) or a A5(10)-3-oxosteroid which 
would be readily isomerized to A4-3-oxosteroid. A5(10)-3-oxosteroid is also a probable 
precursor of 5(10)-estrene-3,17-diol. The reduction of the 3-oxo steroid to form 
5(10)-estrene-3,17-diol stabilizes the A-ring against aromatization. The hydroxyl 
groups was also found to be in 3/3 and YJol configuration. 
At present, many racing authorities, including RHKJC employ only a GC/MS 
method to measure the ratio between 5a-estrane-3jS，17a-diol and 5(10)-estrene-
3j8,17a-diol in the colts urine samples as the detection and confirmatory tool. 
According to the RHKJC, the method requires enzymatic hydrolysis (Houghton et al， 
1985) or methanolysis (Tang and Crone, 1989) of urine samples, followed by thin-
layer chromatography (Dumasiaetal, 1985) or C18-extraction (TealeandHoughton, 
1988) procedures before the residues are derivatized with N-methyl-N-(tert-
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Figure 1.5. Proposed mechanism for the formation endogenous nandrolone 
and 5,(10)-estrene-3，17-diol from testosterone in horses (Smith 
et aL, 1987), see text for explanation. 
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butyldimethylsilyl) trifluoroacetamide to form the tert-butyldimethylsilyl derivatives 
for GC/MS analysis (Houghton et a/., 1985). These procedures are time-consuming 
and they would not be cost-effective to serve as a screening procedure. Therefore, 
there is a need for a better screening method to determine the ratio of these 
compounds in horse urine. 
1.5 Screening of Drugs or Their Metabolites by Immunoassays 
The development of an immunoassay system for quick measurement of 5a-
estrane-3j8,17a-diol to 5(10)-estrene-3j8,17a-diol ratio in colt urine samples would be 
useful as a screening test prior to confirmatory analysis with GC/MS. RIA could be 
used, despite several drawbacks such as the short half-lives of the gamma-emitting 
isotopes, radiation induced of structural damage to the labelled molecules, health 
hazards involving in handling of radioisotopes and a separation step which makes 
automation difficult. To avoid the use of radioactive substances and difficulties in 
separation, ELISA is a good alternative with comparable specificity and sensitivity. 
ELISA practically exists in many different kinds of protocols which have specific 
application (Voller et al.，1979). It could be used to qualify or quantify both antigens 
or antibodies. Basically, ELISA exists in two forms, direct double-antibodies 
sandwich method for determining antigens and indirect method for determining 
antibodies (Figure 1.6). In the direct method, one kind of the antigen-specific 
antibody is immobilized to a solid support. After adding the test sample, a second 
antigen-specific antibody labelled with an enzyme is followed. Then, the activity of 
the enzyme, which has been immobilized to the solid support by the immuno reaction 
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Figure 1.6a. Direct ELISA protocol: An antibody to the antigen is first 
immobilized to a solid support. After subsequent incubation of 
the test sample and a second antigen-specific antibody labelled 
with an enzyme, the activity of the enzyme retained on the 
support will be directly proportional to the amount of antigen 
in the test sample. 
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Figure 1.6b. Indirect ELISA protocol: The antigen of interest is first 
immobilized to a solid support. After subsequent incubation of 
the test sample and a second anti-immunoglobulin antibody 
labelled with an enzyme, the activity of the enzyme retained on 
the solid support will be directly proportional to the amount of 
antigen-specific antibody in the test sample. 
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of the antibodies and antigen, will has a direct relationship to the amount of antigen 
inside the test sample. In the indirect method, the antigen however, is coated to the 
solid support. Test samples with the specific antibody to the antigen will be added and 
a second anti-immunoglobulin antibody (specific to the antibody of interest) labelled 
with an enzyme will be allowed to react. Similarly, the enzymatic activity 
immobilized will, also reflect the amount of antigen-specific antibodies in the test 
sample. 
1.6 Antibodies for Immunoassays 
The initial step for developing an immunoassay system depends on the success 
of raising antibodies specifically against the drugs of interest. Antibodies or 
"immunoglobulins" are, in fact, the products of an animal's immune system. The 
principal function of which is to protect the host animal from infectious organisms 
and from their toxic products. Antibody production is classified as adaptive immunity 
which is different from the "innate immunity" and is more specific and efficient in 
getting rid of the foreign invading agents. Adaptive immunity is mediated by cells 
called lymphocytes which are classified into three basic types: B cells, cytotoxic T 
cells and helper T cells. Production of antibody is mediated by B cells in conjunction 
with helper T cells. . 
Antibodies are animal proteins produced in response to the presence of foreign 
molecules in the body. They are synthesised primarily by a plasma cell, a terminally 
differentiated B cell. They are a large family of glycoproteins that share key structure 
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and functional features. Functionally, they can be characterised by their abilities to 
bind both to antigens and to specialised cells or proteins of the immune system. 
Structurally, antibodies are composed of one or more copies of a characteristic unit 
that can be visualized as forming a Y shape. Each Y contains four polypeptides - two 
identical copies of a polypeptide known as the heavy chain and two identical copies 
of another polypeptide known as the light chain. Antibodies are divided into five main 
classes, namely IgG, IgM, IgA, IgE and IgD, according to the numbers of Y-like 
units and the type of heavy chain polypeptides they contain. Many of the important 
structural features of antibodies are discussed by considering IgG molecules, which 
contains only one structural Y unit and are also the most abundant in animal sera 
(Figure 1.7). Each arm of the Y unit contains an antigen binding site at the very far 
end, hence, making each IgG molecule bivalent. 
1.6.1 Antibody Diversity and Clonal Selection Theory 
The mystery of antibody diversity (specific kind of antibody against a certain 
antigen) is one of the main themes in immunological research. Before the 1950's it 
was widely accepted that antigens must give some kind of "instruction" to control the 
specificity of the antibodies. However, the discovery that proteins had defined 
sequences (Sanger and Thompson, 1953) and the gradual realization that primary 
amino acid sequence was sufficient to specify all the biological activity of a protein 
(Anfinsen, 1973) create great difficulties for instxuctionist theories. Moreover, the 
discovery of DNA, the genetic code, the mechanism of protein synthesis and the 
transfer of information from DNA to protein is essentially one-way, entirely broke 
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Figure 1.7. An IgG molecule (Benjamini and Leskowitz, 1991). 
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down the instructionist theories. In 1957, Burnet postulated that each lymphocytes has 
a unique receptor specificity and is thus precommitted to make only one type of • • 
antibody after appropriate stimulation (Figure 1.8). This theory avoided all the above 
difficulties and is known as clonal selection theory. The first evidence supporting the 
theory was first provided by Nossal and Lederbery (1958). They showed that single 
antibody-forming cells from rats immunized with two different antigens made 
antibody to one or other antigens, but never both. However, it was not until the mid-
1960，s that the theory was generally accepted (Burnet, 1968). The clonal selection 
theory provides the conceptual framework for the antibody production and specificity. 
1.6.2 Antibody-antigen Interactions 
The binding of an antibody with an antigen forms the basis of all 
immunochemical technique. Epitope is the term for the region of an antigens that 
interacts with an antibody. An epitope is not an intrinsic property of any particular 
structure, as it is only referred to the binding sites of an antibody. The size is 
governed by the site of the antigen binding site which could be visualized as a pocket 
into which the epitope docks. 
The binding of antigen to antibody takes place by the formation of multiple 
non-covalent bonds between the epitope and the amino acids of the antigen binding 
sites, these bonds include hydrogen bonds, van der Waals' force, electrostatic bonds 
and hydrophobic bonds. Although they are individually weak in comparison with 
covalent bonds, the multiplicity of the bonds leads to a considerable strong binding 
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Figure 1.8. The clonal selection theory. Interaction of antigen (solid 
triangle) with specific receptor immunoglobulins on the surface 
of clone 2 leads to proliferation and differentiation into cells 
which secrete antibody of the same specificity as the receptor 
(Goding, 1986). 
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force. These non-covalent bonds are critically dependent on the distance between the 
interacting groups, amino acids on the antigen binding site and the functional groups 
I:,:’ 
on the epitope. These groups must be close in molecular view before these bonds 
become significant. As a consequence, for an epitope and an antigen binding site to 
be able to combine means that (a) there must be suitable atomic groups on opposing 
parts of the antigen and the antibody; (b) the shape of the binding site must fit the 
antigen, so several non-covalent bonds can form simultaneously. If the antigen and 
the binding site are complementary in these ways, there will be sufficient binding to 
resist thermodynamic disruption of the bonds. However, if the electron clouds of the 
antigen and antibody overlap, steric repulsive force becomes significant. Hence, the 
overall interaction depends on the balance between the total attractive forces and the 
repulsive forces. This balance plays an important role in the determination of the 
specificity of the antibody molecule for a particular antigen. It is the ability of an 
antibody to discriminate between different antigens, because any variation from the 
ideal complementary shape will cause a fall in binding forces. 
When immunoassay was first introduced for drug analysis, antibodies specific 
to the drug of interest were produced by conventional methods which require 
immunization in host animals and collection of their sera. This antiserum is a mixture 
of antibodies containing a variety of molecules directed against the antigen. According 
to the clonal selection theory (Burnet, 1968), the antibodies are produced by different 
clones of antibody-producing cells of the host body. Each of these antibodies has its 
own characteristics and hence, the properties of a polyclonal antibody preparation is 
the summation of all these antibodies. Properties of antisera produced in this manner 
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would be different from different immunized hosts or in laboratories. Consequently, 
standardization of the immunoassays which based on the antisera is difficult. One of 
the problems in the use of polyclonal antiserum is cross reactivity - caused by the 
presence of antibodies against irrelevant antigens unrelated to the antigen of interest. 
However, a single antibody molecule can also react with unrelated molecules if they 
possess a shared antigenic determinant or epitope. These are the causes of antibody 
cross reactivities and they are presented diagrammatically in Figure 1.9. 
To avoid less than ideal nature of polyclonal antisera, monoclonal antibody 
production could be a usefiil alternative. The theory of monoclonal antibody 
production was originally presented by Kohler and Milstein in 1975. The basic idea 
is that by the somatic cell fusion between an antibody producing cell (B-cell) and an 
immortal cancerous cell (myeloma), the hybrid formed will possess both 
characteristics (antibody production and immortality) of the parent cells. The hybrid 
(or specifically known as hybridoma) grows in culture indefinitely and produces only 
one kind of homogenous antibody with its unique properties. The name given to this 
type of antibody is a monoclonal antibody, which can be obtained in unlimited 
amount, thus, making standardization of immunoassay possible. With its pre-defined 
specificity, cross reactions due to mixture of antibodies against irrelevant antigens 
could be eliminated. Today, hybridoma technology is not only limited to the 
development of immunoassays but is applied in a great variety of fields, from cancer 
diagnosis to the food industry, from organ transplant to plant pathology (Zola, 1987). 
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Figure 1.9. Diagrammatic illustration of the different causes of cross reactivity. 
Cross reactions due to mixed antibodies are absent when using 
monoclonal antibodies, but cross reactions due to shared and similar 
epitopes are found (Zola, 1987). 
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1.7 Antibodies against 5a-Estxane-3iS，17a-diol 
Many anti-steroid antibodies produced by conventional methods, have been 
reported to cross react with some of the endogenous steroids, such as testosterone 
(Abraham, 1975). Since a high degree of specificity is needed to measure 5a-estrane-
3j8,17Qf-diol to 5(10)-estrene-3j8,17a-diol ratio in horse urine by ELISA, monoclonal 
antibodies against the two steroids would be the ideal probes for this purpose. In this 
study, monoclonal antibodies to 5a-estrane-3/3,17of-diol are prepared with a view to 
developing an ELISA suitable for the quantification of this steroid in urine samples. 
In addition to the monoclonal antibody, polyclonal antiserum are also raised in 
rabbits. The antiserum should provide a screening method for the detection of specific 
antibody for polyclonal and monoclonal antibodies. The antiserum would also act as 
a reference to compare the specificity as well as the sensitivity of monoclonal 
antibody. Drugs like steroids are relatively small molecules and are therefore non-
immunogenic. In order to induce antibody production in the host animal, 5a-estrane-
3/3,17a-diol must be conjugated to a protein carrier, such as bovine serum albumin 
or ovalbumin, to increase its immunogenicity. The method of conjugation is modified 
from Jondorf (1977) who has successfully raised antiserum against nandrolone. The 
steroid-protein conjugates synthesised are used for immunization as well as the 
development of an ELISA to detect the subsequent anti-5o;-estrane-3/3,17o;-diol 
activity. After the monoclonal antibody has been characterised, it will be used to 
measure the amount of 5a-estrane-3jS，17a-diol in horse urine samples. The results 
will be compared with those obtained by GC/MS which will give the validation of the 
monoclonal antibody in quantifying 5a-estrane-3j8,17a-diol. 
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1 Chapter 2 
Development of Polyclonal Antibodies against 
5a-Estrane-3]8? 17a-diol 
2.1 Introduction 
The main aim of this study is to develop a suitable enzyme-linked 
immunosorbent assay (ELISA) for the detection of specific anti-5a-estxane-3i(5,17a-
diol antibodies. Antisera against 5a-estrane-3]S,17Q:-diol will be developed for 
establishing the assay which should provide a basis for the further development of 
mouse anti-5of-estrane-3]S，17a-diol monoclonal antibodies (Chapter 3) • The polyclonal 
antibodies could also be used as a reference to compare the sensitivity and specificity 
of the subsequent monoclonal antibodies in recognizing 5a-estrane-3jS，17o:-dioL 
2.1.1 Immunogenicity 
Immunogenicity is the ability of a molecule to induce an immune response. 
It is determined both by the intrinsic chemical structure of the molecules and by 
whether or not the host animal can recognize the compound. Antibodies are 
synthesized by specialized lymphocytes known as plasma cells. These cells are 
differentiated from B cells. The production of a strong antibody response is controlled 
by inducing and regulating the differentiation of B cells to plasma cells. Proteins, 
peptides, carbohydrates, nucleic acids, lipids and many other naturally occurring or 
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synthetic compounds can act as successful immunogens. In general, for a compound 
to elicit an antibody response, it must have an epitope that can bind to the cell-surface 
antibody of a virgin B cell and it must promote cell to cell communication between 
B cells and helper T cells. Binding of the antigen to surface antibody of a virgin B 
cell is an absolute requirement for an antibody response. The specificity of the 
antibodies produced would be determined by this binding. The second property of an 
immunogenic molecule is that it must promote cell to cell communication between 
helper T cells and B cells, i.e. a physical link is set up between them. When an 
antigen enters a B cell, it will be partially degraded and its fragments migrate to the 
cell surface, where they bind to a special kind of protein known as major 
histocompatibility complex (MHC) class II antigen. This complex is then bound by 
the receptor on helper T cells. This connection will trigger the maturation of the 
stimulated B cell into a mature plasma cell which will proliferate and secret 
antibodies. The requirement for both an epitope and a MHC class II antigen-T cell 
receptor binding site imposes a minimum size limit on an immunogen. In practice, 
molecules with a molecular size less than 5,000 are generally not good immunogens 
(Catty and Raykundalia, 1989). Compounds smaller than this can often bind to 
surface antibodies on B cells but may not have suitable sites for the simultaneous 
binding of MHC class II antigen and T cell receptors. Chemical coupling of small 
molecules to larger immunogenic molecules overcomes this problem by providing the 
missing MHC class II antigen-T cell receptor binding sites and allows induction of 
a good antibody response against the small molecules. Those small molecules are 
defined as haptens and the large molecules that render them immunogenic are defined 
as carriers (Roitt et al., 1989). 
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Desirable properties of the hapten-carrier linkage include the ease of 
introduction and the non-masking of immunoreactive sites in the hapten. The former 
is largely a practical consideration for the preparation of the immunogen, and the 
latter may vitally affect the properties of the eventual antibodies. The operation of 
these factors may be considered in relation to some of the existing methods for hapten 
conjugation. Probably the most commonly used approach is based on the method of 
Erlanger et al (1957). The approach was based on a carboxylic acid group, either 
pre-existing or chemically introduced, which is used to form a peptide bond with the 
terminal amino group of lysine residues in the protein. 
Hapten-COOH + NH2-Lys-protein > Hapten-CO-NH-Lys-protein 
Examples of inherent carboxylic acid groups used for this purpose are found in bile 
acids (Simmonds et al, 1973)，steroid glucuronides (Kellie et al, 1972) and 
prostaglandins (Jaffe et al., 1973). There is also a wide variety of means used to 
introduce carboxylic acid group into molecules which could not otherwise be 
conjugated by this method. Carboxylmethyloxime (GMO) (Erlanger et al, 1957), 
thioalkanoate (Rao and Moore, 1976)，hemisuccinate (Steiner et al, 1969), 
alkanamate (Robinson et al, 1975) and carboxymethyl (Spector and Parker, 1970) 
are the best examples. In all these examples, activation of the carboxyl group for 
coupling to the protein can be readily achieved by alkyl chloroformate (Erlanger et 
al, 1957) or with a soluble carbodiimide (Bauminger et al., 1969), to afford 
conjugates in which the hapten remains chemically unaltered and with its unique point 
of attachment clearly defined. In this studies, the steroid 5a-estxane-3iS, 17a-diol is 
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also made immunogenic by conjugating it with bovine serum albumin (BSA), 
ovalbumin (OVA) and sheep serum albumin (SSA). Since this steroid has no inherent 
carboxylic acid group for conjugation, CMO molecules with available carboxylic acid 
groups should be introduced before the conjugation can take place. The BSA 
conjugate will be used for host immunization and the OVA conjugate will be used to 
develop an ELISA for detection of anti-5of-estrane-3j(5,17a-diol activity. 
2.1.2 Immunization and Polyclonal Antibodies Production 
Successful immunization is a prime determinant in both preparation of 
monoclonal as well as polyclonal antibodies. There is no single method for animal 
immunization that guarantees an ideal product. Nevertheless, certain principles can 
be adopted which form the ground rules for an immunization step. 
For practical reasons, rabbits represent a good choice for the routine 
production of polyclonal antisera. They are easy to keep and handle, can be safely 
and repeatedly bled, can provide a relatively large volume of sera for studies and the 
antibodies produced are well characterised and easily purified. However, most 
laboratory rabbits are outbred and, hence, they respond individually, so more than 
one animal should be used for each time of immunization. The use of adjuvant is 
essential to induce a strong antibody response and it seems necessary in any 
immunization experiment. Adjuvants refer to those non-specific stimulators of 
immune response. The most popular choice of adjuvant is Freund's adjuvants 
(Freund, 1956). However, their mechanism of action is not fully understood. Much 
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of the injected materials are catabolized and cleared before reaching an appropriate 
target cell. Thus, the effective dose delivered to the immune system may bear little 
relationship to the actual dose introduced and so descriptions of dose requirements are 
• : 
inevitably empirical. It is wise to follow the work of other people for similar 
immunogens and hosts. If no information is available for a particular immunogen, the 
best way is trial and error. For a soluble protein immunogen mixed with Freund's 
adjuvant a dose of 0.5 - 1.0 mg/animal is recommended for rabbit immunization and 
50 - 100 jLtg/animal for mouse immunization (Harlow and Lane, 1988). The route of 
injection should also be considered and it is guided by the injection volume, 
components with the immunogen and the desired rate of release. For rabbits, large 
volume injections are normally given at multiple subcutaneous sites. For mice, large 
volume injections are only possible by the intraperitoneal route. If slow release of the 
immunogen is desired then the injection should be either intramuscular or 
subcutaneous. After initial injection of an immunogen, antibodies are usually found 
in serum around day 7 and persist at a lower level for a few days. The majority of 
antibodies produced belong to of the class M immunoglobulins (IgM). This is known 
as the primary response and it is often very weak or even undetectable. The initial 
priming of the host animals will establish the immuno-memory for this particular 
antigen. If the antigen is reintroduced later, the antibody response is faster, stronger, 
persists for longer and is qualitatively different. This is known as the secondary 
response. The most important observation in this secondary response is the shift of 
antibody class from IgM to immunoglobulin G (IgG). The response of the third and 
subsequent injection broadly resemble that of the second response. There should be 
a delay between each reintroduction of the immunogen. This is to allow the proper 
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establishment of the immuno-memory for that particular antigen and to prevent rapid 
•靈.： 
clearance of the newly injected immunogen due to high level of circulating antibodies. 
I'；" •： 
In rabbits and mice, the interval between the initial and other boosters is 
recommended as 4 - 6 weeks (Harlow and Lane, 1988). 
In this study, rabbits are immunized by immunization procedures using 
Freund's adjuvants. The antisera obtained will be used to develop an ELISA for the 
detection of antibodies against 5o;-estrane-3i(5,17of-dioL 
I 
‘ . . • 
• • , • 
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I 2.2 Materials and Methods 
•fez. 
2.2.1 Reagents and Apparatus 
Bovine serum albumin (fraction V; BSA), ovalbumin (grade V; OVA), sheep 
serum albumin (fraction V; SSA), l-ethyl-3-(-3-dimethylaminopropyl-)-carbodiimide, 
Freund's complete and incomplete adjuvants (FCA, FIA), anhydrous citric acid, o-
phenylenediamine (OPD), goat anti-rabbit IgG (whole molecule), rabbit anti-goat IgG 
1 
(peroxidase labelled) were purchased from Sigma (St. Louis, MO, USA). Tween 20, 
hydrogen peroxide (30 %), ethyl acetate, phosphates salts, sodium chloride and 
sodium sulphate (all AR grade) were supplied by E. Merck (Darmstadt, Germany). 
Methanol (HPLC grade), sulphuric acid (H2S04; 98 %; AR grade) and hydrochloric 
acid (HC1; 37 %; AR grade) were from Mallinckrodt (Paris, KN, USA). 
Carboxymethyloxime hemihydrochloride (CMO) and pyridine were from Aldrich 
(Milwaukee, WI, USA). MOX (2 % methoxyamine HC1 in pyridine) was purchased 
from Pierce (Rockford, IL, USA). Regisil (N,0-bis(trimethylsilyl)-trifluoroacetamide 
and 10 % trimethylsilyl chloride) was provided by Chrompack (Middelburg, The 
Netherlands). All steroids were kindly provided by Dr. Francis P.W. Tang of,the 
Racing Laboratory, The Royal Hong Kong Jockey Club (RHKJC). 
ELISA microtitre plates (Microtest III) were from Falcon (Oxnard, CA, 
USA). Dialysis tubings (cut off: mol. wt. > 12,000) were also supplied by Sigma. 
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2.2.2 Preparation of 5a-Estrane-3j8-ol-17-carboxymethyloxime-protein conjugates 
The conjugates were synthesized using a modified method of Jondorf (1977). 
The preparation, as outlined in Figure 2.1, includes the addition of carboxyl group 
to the steroid molecule and the linking of the carboxyl group to the terminal amino 
group on the protein carrier. 5a-Estrane-3iS-ol- 17-one (1 mmol, 0.276 g) and 
carboxymethyloxime hemihydrochloride (1 mmol, 0.218 g) were dissolved in dry 
pyridine (8 mL). The mixture was stirred overnight in darkness at room temperature. 
Pyridine was then removed by evaporating under nitrogen. HC1 (2 M, 5 mL) was 
added to the mixture, followed by extraction with ethyl acetate (15 mL x 2). The 
organic extract was dried with anhydrous sodium sulphate and concentrated to give 
a final white powder of 5a-estrane-3/3-ol-17-carboxymethyloxime (EaCMO). EaCMO 
was checked for purity by gas chromatography/mass spectrometry (GC/MS) analysis 
on tert-butyldimethylsilyl derivatives (Tang and Crone, 1989). Aliquot (5 mL) of 
EaCMO (1 /xg/mL in methanol) in duplicate was dried at 60�C under nitrogen (N2). 
MOX (40 [A) was added to the residues and incubated at 60°C for 20 minutes. The 
solvent was evaporated also at 60°C under N2 and Regisil (50 /xL) was added. 
Incubation at 60°C for anther 20 minutes. Aliquots (1 /jlL) was analyzed by GC/MS. 
Briefly, GC/MS was performed using a gas chromatograph (Varian model 3400, 
Sunnyvale, CA, USA) connected to an ion-trap detector (ITS40, Finnigan Mat, San 
Jose, CA, USA). The column (a cross-linked dimethyl silicone capillary; 12.5 m X 
0.2 mm i.d•； Ultra 1; Hewlett-Packard, Avondale, PA, USA) was held initially at 
150°C for 1 minute, then heated at 15°C per minute to a final temperature of 300°C 
and held at 300�C for 5 minutes. Injections were splitless. 
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5a-estrane-3/3-17-one EaCMO 
Part I. Synthesis of 5a-estrane-3j3-17-carboxylmethyloxime (EaCMO) 
Part II.Linking of EaCMO to protein carriers (BSA, OVA or SSA) 
；NH 
N-0-CHrC0-NH-Lys ( 
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\ / Protein H N \ ^ 4 (BSA, OVA or SSA) 
H NH 
HN 
\ — Lys-NH-C0-CH2-0-N 
EaCMO-protein conjugate I I 
H 
Figure 2.1. Schematic diagram for the synthesis of 5a-estrane-3jS-17-
carboxylmethyloxime-protein conjugates 
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l-Ethyl-3-(-3-dimethylaminopropyl-)-carbodiimide hydrochloride in aqueous 
pyridine (50 mg in 0.5 mL 50 % v/v aqueous pyridine), was added, dropwise, with 
stirring, to EaCMO (50 mg) in aqueous pyridine (50 % v/v, 0.5 mL) at room 
temperature. BSA (100 mg) in distilled water (2 mL) was then added dropwise in one 
hour with continuous stirring. After stirring for 24 hours, the mixture was dialysed 
against distilled water (5 L) for 24 hours with four changes of water. The dialysate 
was then lyophilized and stored desiccated at 4°C. Other steroid-protein conjugates 
with OVA and SSA were synthesized with the same method. All steroid-protein 
conjugates (1 mg/mL), EaCMO (0.1 mg/mL) and protein carriers (lmg/mL) were 
scanned for their ultraviolet (UV) absorption spectra (200 - 400 nm) for determining 
I 
their epitope density (Erlanger et al , 1957). 
2.2.3 ImmunizationofRabbitswith5a-estrane-3iS-ol-17-carboxymethyloxime-bovine 
serum albumin (EaBSA) 
EaBSA (15 mg) was dissolved in physiological saline (0.85 % w/v, 7.5 mL) 
and FCA (7.5 mL) was added (FIA was used for the second and subsequent 
immunization). The water-oil mixture was then emulsified by two syringes connected 
with a double-hub needle (Herbert, 1973). Emulsification took place when the mixture 
was passed rapidly back and forth between the syringes a few dozen times. The 
emulsion was tested by allowing a drop to fall onto the surface of a beaker of water, 
which remains as a discrete globule. 
Male New Zealand white rabbits (2 - 2.5 kg) were housed in individual metal 
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cages and allowed free access to rabbit chew and water. A 12 hours light and dark 
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cycle was maintained in the holding area. Each rabbit was immunized with a total of 
3 mL drug-protein conjugate emulsion: 1 mL intramuscularly to each hind leg，and 
I 參 
1 mL in divided doses in four subcutaneous sites on the back skin (0.25 mL for each 
site). Injection were repeated at monthly interval. Blood samples from each rabbit 
prior to immunization and on day 14 after each injection were obtained from the ear 
vein. Blood was allowed to clot overnight at room temperature. Serum was obtained 
by centrifugation (3,000 r.p.m. for 10 minutes). The serum was stored as 1 mL 
aliquots at -20°C. 
2.2.4 Enzyme-linked Immunosorbent Assay (ELISA) 
The specific anti-5a-estrane-3]S, 17a-diol antibody activity was determined by 
using an indirect enzyme-linked immunosorbent assay (ELISA) method (Yeung et al， 
1985)，as shown in Figure 2.2. Microtitre plates (Falcon Microtest III) were coated 
with 5a-estrane-3i8-ol-17-carboxymethyloxime-ovalbumin (EaOVA) or OVA (0.01 
mg/mL, 125 /xL/well) in coating buffer (0.05 M phosphate buffer, pH 7.2) at 4°C 
overnight in a humidified chamber. On the next day, the plates was washed 3 times » 
with PBS-Tween (0.15 M phosphate buffer, pH 7.2, contains 0.9 % w/v sodium 
chloride and 0.05 % v/v Tween 20, freshly prepared) and shaken dry. All 
subsequent washes were performed in the same manner with PBS-Tween. PBS-Tween 
was also used as the dilutant for all sera and anti-sera. The plates were then incubated 
at room temperature in a humidified chamber for one hour with each of the following 
reagents, with washing between each step: test sera (100 /iL/well) at the initial 
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Coat plates with 0.01 mg/ml 
EaOVA/OVA in coating 
buffer: 125 /iL/well 
1 
wash 3 times with 
PBS-Tween and shaken dry 
i 
incubate with the test 
samples for 1 hour at 
room temperature 
1 
wash 3 times with 
PBS-Tween and shaken dry f 
incubate with goat 
anti-rabbit IgG 
(1:1000): 100 /iL/well 
for 1 hour at room 
temperature 
I 
wash 3 times with 
PBS-Tween and shaken dry 
i 
incubate with rabbit 
anti-goat IgG 
peroxidase labelled 
(1:1000): 100 /iL/well 
for 1 hour at room 
temperature 
i 
wash 3 times with 
PBS-Tween and shaken dry 
I i 
incubate with substrate 
solution: 100 /xL/well for 
20 mins. at room 
temperature 
. : i 
stop reaction by 
adding 25 % H2S04: 50 
/iL/well 
: i 
read absorbance at 490 nm 
Figure 2.2. The schematic flow diagram of ELISA procedures for the 
detection of anti-5a-estrane-3]S, 17a-diol IgG activity. 
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dilution of 1:100 serially diluted (5-fold) down columns; goat anti-rabbit IgG (100 
/xL/well, 1:1000 dilution); rabbit anti-goat IgG (peroxidase labelled) (100 ^L/well, 
• 會 . . . 
1:1000 dilution); substrate solution (100 /zL/well, containing 0.1 % v/v hydrogen 
peroxide and 400 鮮 g / m L OPD in 0.15 M citrate-phosphate buffer, pH 5.0). The 
reaction was quenched by adding 25 % v/v H2S04 (50 pL/well) after 20 minutes. 
Absorbance at 490 nm of each well was read by a dual wavelength automatic 
microplate reader (Dynatech, model MR 710)，with the reference wavelength set at 
630 nm. 
Antibody litres were calculated as dilution of anti-sera given and absorbance 
� " 
of 0.5. Anti-5a-estrane-3jS, 17a-diol IgG activity was defined as the antibody titre 
following coating of plate with EaOVA, when no activity was detected against OVA 
alone. 
To determine the intra-assay coefficient, rabbit antiserum (100 /xL, 1:1000 
dilution) was added to each well of a EaOVA coated microtitre plate. The plate was 
then subjected to the ELISA procedures as described. Intra-assay coefficient was 
calculated as the coefficient of variation (standard derivation/mean x 100 %) 
between 96 wells on the plate. Four 96-well plates were set up with the same 
treatment as described. The interassay coefficient was calculated as the mean 
coefficient of variation between these plates. 
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2.2.5 Inhibition ELISA Analysis 
The specificity of the anti-5a-estrane-3i3,17a-diol antibodies after I 
immunization was determined by inhibition studies. The cross reactivity of the 
• • • • ‘ 
antiserum with different carrier proteins and structurally related steroids was 
. 
evaluated. The antiserum was preincubated with carrier proteins, the steroid-protein 
I 
conjugates and other steroids before the ELISA was performed as previously 
described. 
Briefly, serial dilution of various potential inhibitors were prepared (0.2 - 100 
/ig/mL) in PBS-Tween. Aliquots (I5O7XL) of each inhibitors were mixed with rabbit 
antiserum (150 pL, 1:1000 dilution) and incubated at 4 � C overnight. The supernatant 
were then used in the ELISA for detecting the specific anti-5a-estrane-3i(?, 17o;-ciiol 
IgG activity. The potential inhibitors used in the study included steroid-protein 
conjugates (EaBSA, EaOVA and 5a-estrane-3jS-ol-17-carboxymethyloxime-sheep 
serum albumin (EaSSA)), the unconjugated carrier proteins (BSA, OVA and SSA) 
and 46 structurally similar steroids (Table 2.1). For the steroid inhibition study, a 
methanol control was used, since all steroids were dissolved initially in methanol as 
stock solutions. 
2.2.6 Calculation of Cross Reactivity 
The cross reactivity of each inhibitor relative to 5a-estrane-3/3,17-of-diol was 
determined by establishing their inhibition standard curves from the data obtained in 
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Table 2.1. 46 steroids used in inhibition ELISA analysis 
|| . 
K*1 丨 : ： ‘ II , I f . 1. 5of-Androstane-3iS, 17o:-diol 24. 5or-Estrane-3a, 17j3-diol 
I 
2. 5a-Androstane-3j8,17j8-diol 25. 5a-Estrane-3jS,17o!-diol 
3. Androstenediol 26. 5a-Estrane-3jS,17/3-diol 
4. Androstenedione 27. ^-Estradiol 
5. Androsterone 28. Estradiol 
I j ' 
6. Betamethasone 29. Estratriol 
7. Boldenone 30. 4-Estrene-3j8,17jS-diol 
8. Corticosterone 31. 5(10)-Estrene-3,17-dione 
9. Cortisone 32. 5(10)-Estrene-3of,17/3-diol 
10. 11-Dihydrocorticosterone 33. 5(10)-Estrene-3jS, 17a-diol 
11. Dehydroepiandrosterone 34. Estrone 
12. Dexamethasone 35. Hydrocortisone 
13. Dihydroandrosterone 36. Methandriol 
14. 5a-Dihydrocortisol 37. Methylandrostanolone 
15. 5/3-Dihydrocortisol 38. Methylprednisolone 
16. 5a-Dihydrotestosterone 39. Methyltestosterone 
17. Epiandrosterone 40. Nandrolone 
18. Epitestosterone 41. Prednisolone 
19. 5a-Estrane-3a-ol- 17-one 42. Prednisone 
20. 5a-Estrane-3i8-ol- 17-one 43. Progesterone 
21. 5a-Estrane-3jS-ol- 17-CMO 44. Stanozolol 
22. 5a-Estrane- 17of-ol-3-one 45. Testosterone 
23. 5a-Estrane- 17j8-ol-3-one 46. Trenbolone 
I ." > 
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inhibition ELISA. For example, the inhibition curves for steroid X and steroid Y 
I 
could be set up as follows: 
1¾ 
� 
I I C v ^ 
I ‘ “1� 1 1 
Log [Steroid Concentration] 
The 50 % inhibition concentration (IC50) of X and Y were the concentrations that 
inhibited half of the ELISA reaction. The cross reactivity of the anti-X antiserum to 
steroid Y could be expressed in cross reactive percentage (CR %). Then, 
IG50 of X 
CR % = x 100 % 
IC50 of Y 
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2.3 Results 
I 
2.3.1 Characterization of the Steroid-Protein Conjugates 
[$.： . . . . . ' 
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In GC/MS analysis, EaCMO expressed a peak of highest abundance at the 
I 
retention time 15.2 minutes. The mass spectrum of this fraction suggested the 
structure of EaCMO is as follows: 
N-0-CH,C00H 
I H O ^ ^ i ^ 
H 
by monitoring the ions 331, 346, 478 and 493. 
The UV spectrum of EaCMO (mol. wt.: 349; 0.1 mg/mL) showed that the 
wavelength of maximum absorption (X^.) was at 255 nm and the absorbance was 
0.5. Hence, the molar extinction coefficient (S) at 255 nm was calculated as 
following, 
absorbance 
E = ^ 
number of mole/litre 
and equal to 1745. Similarly, the X^. of BSA (mol. wt.: 68000; 1 mg/mL) occurred 
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at 277 nm and E was found to be 19380. EaBSA (0.01 mg/mL) exhibited absorbance 
of 0.06 and 0.0088 at wavelength 255 nm and 277 nm respectively and BSA (0.01 
mg/mL) also showed an absorbance of 0.04 at 255 nm. Hence, the difference (0.06 -
If. 
0.04 = 0.02) between the absorbance of EaBSA and BSA at this wavelength 
I 
represents the contribution of EaCMO to the absorbance. Based on the assumption 
that E of EaCMO will remain the same after conjugation to the protein (Erlanger et 
al, 1957), the EaCMO residue is 0.02/1745 = 1.146 x 10"5 mol/L. Under the same 
assumption and since EaCMO did not contribute to the absorption at 277 nm, the 
concentration of BSA in EaBSA would be 4.54 x 10"7 mol/L. Consequently, the 
amount of EaCMO residues attached to each mole of EaBSA (epitope density) is 
I 
1.146 X 10"5/4.54 X 10'7 =25. According to the same method of calculation, the 
epitope densities of EaOVA and EaSSA are 26 and 32 respectively. 
2.3.2 Anti-5a-estrane-3iS, 17a-diol IgG Activity in Sera of EaBSA Immunized 
Rabbits 
Anti-sera from all four rabbits immunized with EaBSA showed anti-5of-
estrane-3]8,17a-diol IgG activity. The time course of the appearance of anti-5a-
estrane-3/3,17a-diol specific IgG in sera of EaBSA immunized rabbits was shown in 
Figure 2.3. The results also indicated that there were no further increase in anti-5ce-
estrane-3jS,17oj-diol IgG antibody titxe after the 1st booster dose. Since anti-serum of 
rabbit no. 2 sampled on day 14 after 1st booster dose showed the highest antibody 
titxe, this sample, 2-1B, was used for further investigation in inhibition studies. 
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Rabbit No. 1 
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Figure 2.3a. Time courses of appearance of anti-5o!-estrane-3j(3,17o;-diol 
antibody (IgG) in the serum taken on day 14 after the initial 
immunization ( • ) ， d a y 14 after 1st booster (•) and day 14 after 
2nd booster ( • ) of EaBSA injection, compared to the pre-
immunization serum (x) of rabbit number 1 & 2. Anti-5of-
estrane-3j8,17of-diol IgG activity was measured by ELISA. 
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Figure 2.3b. Time courses of appearance of anti-5of-estrane-3j(3,17of-diol 
antibody (IgG) in the serum taken on day 14 after the initial 
immunization (•) , day 14 after 1st booster ( • ) and day 14 after 
2nd booster ( • ) of EaBSA injection, compared to the pre-
immunization serum (X) of rabbit number 3 & 4. Anti-5a-
estrane-3j8,17of-diol IgG activity was measured by ELISA. 
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2.3.3 Antiserum Cross Reactivity 
Inhibition studies showed that the specific anti-5a-estrane-3/3,17a-diol IgG 
activity was inhibited by preincubation with EaBSA, EaOVA and EaOVA, but not the 
respective carrier protein (Figure 2.4). The results confirmed the specificity of the 
I! 
antibody. Inhibition studies with the hapten and other steroids showed that five of the 
steroids which have the common 5a-estrane-3-ol structure, exhibited strong inhibition 
of the antibody activity (Figure 2.5). 
xb 
f h o ^ A ^ 
H 
5oj-estrane-3-ol structure 
The steroids included EaCMO, 5a-estrane-3/3-ol- 17-one, 5a-estrane-3i8,17a-diol, 5a-
estrane-3jS,17/5-diol, and 5a-estrane-3a, 17jS-diol. The cross reactivities with respect 
to 5a-estrane-3j8,17o;-diol is shown in Table 2.2. The antibody is more specific 
against EaCMO and 5a-estrane-3i8-pl-17-one than 5of-estrane-3jS, 17of-diol. The 
antibody exhibited a dose response relation with 5of-estrane-3/3,17a-diol in the 
concentration range of 0.1 to 10 pg/mL. Expected stereo-specific discrimination 
between stereoisomers of 5oj-estrane-3/3,17ce-diol is rather weak. Other inhibiting 
steroids were listed in Table 2.2. However, their cross reaction (CR %) was limited 
within the range between 2 - 23 %. It should be noted that both nandrolone and 
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Figure 2.4. Inhibition ELISA of anti-5a-estrane-3j(3,17a-diol IgG activity after 
preincubation of rabbit antiserum, 2-1B (obtained on day 14 after 1st 
booster of EaBSA immunization; 1:1000 serum dilution) with various 
concentration of EaOVA ( • ) ， E a S S A ( • ) ， E a B S A ( •) and OVA (X). 
Other carrier proteins (BSA, SSA) showed inhibition curves similar to 
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Figure 2.5. Inhibition ELISA of anti-5a-estrane-3)S, 17a-diol IgG activity after 
preincubation of rabbit antiserum, 2-IB (obtained on day 14 after 1st 
booster of EaBSA immunization; 1:1000 serum dilution) with various 
concentration of steroids: EaCMO ( • ) ， 5 o f - e s t r a n e - 3 / 3 - o l - 1 7 - o n e (•), 
5a-estrane-3/3,17a-diol(•), 5a-estrane-3a, 17jS-diol(•)and methanol 
(X). The inhibition curve of 5a-estrane-3j8,17/3-diol was similar to 
5a-estrane-3a, 17/?-diol and was omitted in this figure. 




Table 2.2. Cross-reaction of polyclonal rabbit anti-serum, 2-B1 
(obtained by EaBSA immunization), to various steroids. • 
CR% 
Cross Reacting Steroids : 
5of-Estrane-3/5,17a-diol 100% 
5of-Estrane-3j(?-ol-17-one > 100% 
5a-Estrane-3](3-ol-17-CMO > 100% 
5a-Estrane-3of, 17]S-diol 42.6% 
5a-Estrane-3/3,17/3-diol 45.1% 




5ce-Estrane-3a-ol- 17-one 7.7% 
4-Estrene-3j8,17i8-diol 22.8% 
5(10)-Estrene-3,17-dione 2.0% 
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testosterone were also considered to be cross-reacting species. Other steroids tested 
had their IC50 values well outside the range of concentration investigated. Their CR 
% was smaller than 1 % and they were not considered as cross-reacting species. 
2.3.4 Intra- and Inter-assay Coefficients 
I 
The intra-assay and inter-assay coefficients of variation of the ELISA assays, 
using antiserum 2-1B, were 1.94 % and 2.25 % respectively. 
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5of-estrane-3iS, 17a-diol is one of major urinary metabolites of anabolic steroid 
nandrolone in horses. In this study, 5of-estrane-3iS,17a-diol was conjugated to a 
protein carrier (BSA, OVA and SSA) by substitution of a CMO group at C17 • “ • 
I 
position; this provided a terminal carboxylic acid group for the formation of a peptide 
bond between the terminal amino group on the lysine residues on the protein carriers. 
The immunization of EaBSA in rabbits gave rise to specific anti-5Qf-estrane-3j8,17a-
diol antibodies as detected by ELISA. The specificity of the anti-5a-estrane-3jS, 17a-
diol antibody was confirmed, based on the three criteria as previously described 
(Yeung et al.，1985): (a) the antibody reacts with the immobilized EaOVA conjugate, 
but not to the immobilized unconjugated OVA, (b) the reaction is inhibited by the 
preincubation of the antiserum with steroid-protein conjugates (EaBSA, EaOVA and 
EaOVA), but not with the same unconjugated protein carriers, (c) the reaction is 
blocked by the pre-incubation of the antiserum with 5a-estrane-3]S, 17a-diol alone, but 
not with other steroids. There was no significant anti-OVA IgG activity detected in 
the antisera; the ELISA reaction would be due to 5a-estrane-3jS, 17o:-diol residue on 
the immobilized steroid-protein conjugate with the antibody. 
The specificity of the antibody was determined by inhibition studies. The 
antiserum did not show any cross reactivity to the carrier proteins. Inhibition was 
observed with the 5a-estrane-3/?, 17o:-diol conjugated proteins. These results further 
validated the ELISA reaction was determined by the specific binding between 
polyclonal antibodies and the 5Qj-estrane-3/3，17ce-diol residues on the immobilized 
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EaOVA conjugate. 
The cross reactivities of the antiserum to other steroids were also investigated. 
The antiserum cross reacted with 5 structurally very similar steroids, including 5a-
estrane-3jS,17a-diol (Figure 2.6). The epitope or the antigenic determinant is thought 
to be the 5a-estrane-3-ol structure which is the backbone structure of all 5 strongly 
cross-reacting species. The antiserum exhibits a weaker affinity to 5o;-estrane-3i8,17a-
diol than EaCMO or 5a-estrane-3]8-oI-17-one which showed strongest inhibition in 
the analysis (Figure 2.5). It is because EaCMO is a residue on the immunogen 
EaBSA and 5o:-estrane-3iS-ol-17-one is only structurally different from EaCMO at 
C17 position, at which a =N on EaCMO was substituted with a = 0 on 5a-estrane-
3]S-ol-17-one. The antibody also expressed a weak ability to differentiate the 
diastereoisomers of 5a-estrane-30,17]8-diol and 5o:-estrane-3Q；, 17/3-diol. It would be 
expected that stereoisomeric changes may affect the recognition of the antibody to 
those isomers but only weak diminishing in cross reactivities were observed in this 
study. The antibody was unable to discriminate 17a and 17/3 isomers. It may be due 
to the fact that the C17 position is the point of conjugation between the steroid and 
the protein and therefore the prime recognition site in the steriod-protein conjugate 
(immunogen) should be distal to the site of conjugation and the antibody would be 
insensitive to any changes at this point (Niswender and Midgley, 1970; Spector and 
Parker, 1970; Bauminger et al，1975). The expected differentiation between 2>a and 
3/3 isomers (since the immunogen is in 3/3 configuration) did not occur. This may be 
due to the contamination of 5a-estrane-3o;-ol-17-one in the starting material used in 
synthesis of the steroid-protein conjugates which would lead to the production of 
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5a-estrane-3j(J, 17/?-diol 5a-estrane-3a, 17/?-diol 
Figure 2.6. The structures of five strongly inhibiting steroids with rabbit 
antiserum, 2-1B, in inhibition ELISA analysis. 
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antibodies against the 3a isomer. When a comparison of the cross reactivities to 5a-
• . , . 
estrane-17ce-ol-3-one and 5a-estrane- 17/3-ol-3-one is made, their cross reactivities 
were reduced as the structure is changed from 3-hydroxyl group in 5a-estrane-
3jS,17o:-diol to a 3-keto group. In addition, the change in configuration of the 17-
hydroxyl group did not affect the relative cross reactivities of these two steroids. 
When backbone structure is change from 5a-estrane-3-ol structure to 5(10)-estrene-3-
ol structure, the overall cross reactivity was greatly decreased. 
• i _ I 作 II I 
5(10)-estrene-3-ol 
Other steroids, such as nandrolone and testosterone, also cross react with the 
antibody. It is interesting to note that the antiserum raised against nandrolone 
(Jondorf, 1977) also expressed cross reactivities against 5a-estrane compounds as well 
as testosterone. The configurational factors of the ring connection in the steroid 
structure have been implicated in these observations (Kohen et al., 1975). The form 
of alignment of the steroid A-ring and B-ring at their junction closely resembled 
between nandrolone and the 5o;-estxane compounds (Jondorf, 1977). Nevertheless, 
relatively higher cross reactivity of 4-estrene-3/3,17jS-diol could not be explained. 
In summary, an ELISA has been established to detect specific rabbit anti-5a-
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estrane-3/3,17of-diol IgG antibodies. The cross reactivity of the antibody was clarified 
by inhibition studies using 5a-estrane-3]8,17a-diol conjugated proteins and other 
steroids. The ELISA method thus provided a screening method for the detection of 
specific anti-5of-estrane-3/3,17of-diol antibodies, which would form the basis of the 
• • 




Development of Monoclonal Antibody against 
5o:-estrane-3i8,17a-diol 
3.1 Introduction 
5a-Estrane-3jS, 17a-diol (glucuronide) and nandrolone (sulphate), excreted as 
urinary conjugates, are the major metabolites of nandrolone in horses (Houghton, 
1977; Houghton and Dumasia, 1980; Dumasia and Houghton, 1984). Detection of 
these steroids in urine is regarded as the confirmation of the administration of 
' nandrolone in geldings and fillies (Houghton et al., 1978; Houghton and Teale, 
• 
1981). However, the presence of 5a-estrane-3/3,17of-diol and nandrolone in normal 
urine from colts (Houghton et al., 1984) precludes their use as indicators for 
nandrolone administration in this type of racing horses. The measurement of urinary 
5ce-estrane-3jS, 17a-diol to 5(10)-estrene-3]8,17a-diol ratio in urine is used to detect 
nandrolone administration in colts. 5(10)-estrene-3/?, 17o:-diol is not a metabolite of 
nandrolone and it is a usually present in colts，urine samples (Houghton et al.，1984). 
It is believed to be a metabolite of endogenous testosterone (Smith et al.，1987) and 
the ratio of 5a-estrane-3]S, 17ce-diol to this steroid in normal colts' urine was found 
to be less than unity (Houghton et al.，1985). Therefore, a 5oj-estrane-3jS，17a-diol to 
5(10)-estrene-3j8,17a;-diol (estrane/estrene) ratio greater than one would be indicative 
of nandrolone administration in the horses concerned (Houghton et al., 1985). 
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Current methods for measuring the estrane/estrene ratio requires enzyme 
hydrolysis (Houghton et a/., 1985) or methanolysis (Tang and Crone, 1989) of the 
urine samples followed by a thin layer chromatography (Dumasia et al.，1985) or C18 
cartridge extraction (Teale and Houghton, 1988) procedures. The residues are 
‘ ‘ . 
derivatized with N-methyl-N-(tert-butyldimethylsilyl)-trifIuoroacetamide to form the 
tert-butyldimethylsilyl derivatives for gas chromatography and mass spectrometry 
(GC/MS) analysis (Houghton et al.，1985). These procedures are time-consuming and 
is not ideal for screening a large number of samples. 
Immunoassay, such as enzyme-linked immunosorbent assay (ELISA), could 
be used as a screening method for the estrane/estrene ratio in colts' urine samples. 
The positives in the initial screening are then subjected to final confirmation by 
GC/MS analysis. Following the development of an ELISA to determine anti-5a-
estrane-3j8，17a-diol activity (chapter 2), studies to produce monoclonal antibodies 
against 5of-estrane-3jS, 17a-diol are undertaken and described in this chapter. This 
would form the initial part of estrane/estrene diol ratio determination assay and 
provide another means of detecting of nandrolone administration in geldings and 
fillies. 
3.1.1 Monoclonal Antibody 
Polyclonal antibodies create a variety of problems in immunochemical 
techniques due to their cross reactivities. Therefore, preparation of homogenous 
antibodies with defined affinity and specificity was a long standing goal of 
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immunochemical research. In animals, antibodies are synthesized by plasma cells. 
Each plasma cell will proliferate and its clonal population will be responsible for the 
11:,..:.......... . . 
production of only one kind antibody (Burnet, 1968). Because plasma cells cannot be 
grown in culture, they cannot be used as a source of antibody in vitro. In 1975， 
Kohler and Milstein developed a technique that allows the growth of clonal population 
I 
of cells secreting homogenous antibodies with defined properties. In this technique, 
an antibody-secreting cell, isolated from an immunized animal, is fused with a 
myeloma cell, a type of B cell tumours. The hybrids or hybridomas will retain the properties of their parent cells. These cells can be maintained in vitro virtually • . 
• 5, . . . • ‘ ' 
forever and secret homogenous antibody with unique characteristics. Such kind of 
antibody is known as monoclonal antibody. The application of monoclonal antibody 
are widespread. After about 20 years refinement of the technique, the preparation of 
monoclonal antibody is done in a rather standard and routine way. The practical 
aspects of the technique is well documented and will be reviewed in the following 
paragraphs. 
3.1.1.1 Somatic Cell Fusion (Hybridization) 
The development of cell fusion or hybridization techniques is an important part 
in monoclonal antibody technology. The fusion enables the genetic materials from two 
types of cells to be grouped together and functioned in a hybrid. In performing 
hybridization experiment the following three considerations should be taken into 
account, namely, fusion partners, fusing agents and hybrid selection. 
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3.1.1.1.1 Fusion Partners 
I? 
i ' : . : . , , . . � • . II . 
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Myeloma or B-cell tumour can be induced in a few strains of mice by 
I 
intraperitoneal administration of mineral oil. The first example was done by Potter 
I 
(1972) who induced and isolated this cell in balb/c mice. The cells were referred to 
mineral oil plasmacytoma (MOPC) and derivatives of it have been used commonly 
I 
I • 夢 ^ ” 。 . ！： 
as partners for hybridization. Table 3.1 lists some of the myeloma cell lines used for 
hybridoma preparation. Myelomas have all the cellular machineries necessary for the 
• 
secretion of antibodies and may secrete these proteins. To avoid the production of 
• . ‘ • • � . . . . . . : . : • . 
• ‘ 
hybridomas that secret more than one type of antibody, myelomas used for 
hybridization have been selected for the lack of antibody production. The other 
partner of fusion is isolated from immunized animals. The cells must contain the 
necessary genetic materials for the production of the desired antibody. Due to 
practical difficulties in purifying these cells, hybridization is normally done with 
mixed population of cells isolated from a lymphoid organ (generally is the spleen) of 
a successfully immunized host. All commonly used mouse strains can serve as 
successful antibody-secreting cell donor with balb/c derived myelomas. 
3.1.1.1.2 Fusing Agents 
The fusion between any kind of cell types can be induced by a fusogen. In the 
model given by Kohler and Milstein, Sendai virus was used as a fusogen, but in later 
years, polyethylene glycol (PEG) has been use extensively and in virtually all kinds 
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Table 3.1. Commonly used myeloma cell lines for hybridoma production (Zola, 
I 1987). 
I k. . 
. . . . . . . 
Chains 
Cell line Derived from expressed Secreting 
• • • ' • : ‘ • 
I 
Mouse Lines 
P3-X63Ag8 P3K yl, K I g h 
X63Ag8.653 P3-X63Ag8 None No 
Sp2/0-Agl4 P3-X63Ag8 x BALB/c None No 
FO Sp2/0-Agl4 None No 
NSI/l-Ag4-l P3-X63Ag8 Kappa No 
NSO/1 NSI/l-Ag4-l None No 
FOX-NY NSI/l-Ag4-l Kappa (?) No 
Rat Lines 
Y3-Agl.2?3 Y3 Kappa No 
YB2/0 YB2/3HL None No 
IR983F LOU/c rats None No 
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on two distinct phases (Knotton and Pasternak, 1979; Wojcieszyn et al., 1983): cell 
• ？ P -
, . , , .,. 
agglutination, during which the plasma membranes of adjacent cells are brought into 
close proximity followed by the formation of cytoplasmic bridges between cells. 
• ‘ 
These phases are followed by osmotic cell swelling and heterokaryon formation. In 
• 
the early 1980's, an entirely different approach of fusing cells was proposed. It is 
known as electrofusion (Zimmerman and Scheurich, 1981; Bischoff et al., 1982). 
Cells were oriented by a non-uniform electric field and fusions were induced by 
applying a pulse of high frequency energy. However, this method did not gain wide 
popularity, partly because of its high equipment cost. 
� • . 
3.1.1.1.3 Hybrid Selection 
• 離 ’ . . 
Even in the most efficient hybridoma fusion experiment, only about 1 % of 
the starting cells are fused and only about 1 in 105 cells form viable hybrids. This 
leaves a large number of unfused cells still in the culture. The cells from immunized 
animals do not continue to grow in culture and so do not interfer with the further 
works. However, myeloma cells are well adapted to the culture environment and must 
be eliminated. The selection system used almost universally is the HAT system 
(Littlefield, 1964). In this system (Figure 3.1), aminopterin (A in HAT) is used to 
I 
» . 
block the main biosynthetic pathway for nucleic acids. Normal cells can continue to 
synthesize nucleic acids using the salvage pathway, providing that they are supplied 
� ‘ 
with hypoxanthine and thymidine (H and T in HAT). Mutant cells which lack one of 
. 
the enzymes in the salvage pathway cannot proliferate in the presence of aminopterin 
and die out. Mutant myelomas, lacking the enzyme hypoxanthine guanine 
,； ： ： . : 
I::... .. 
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Figure 3.1. The HAT selection system in hybridoma production (Littlefield, 
1964). See text for explanation. 
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phosphoribosyl transferase (HGPRT) have been prepared. These cells are used as 
I .. •, . . 
parent myeloma in the fusion and will multiply in the absence of aminopterin, but die 
in HAT medium. Hybrids, which have a HGPRT gene from the normal parent spleen 
‘ . . …. 
cell, survive in HAT medium. The myeloma lines have occasionally been reported 
to revert to cell types which grow in HAT medium. If this happens, or as a 
precaution, the cell may be selected by culturing in the presence of 6-thioguanine or 
8-azaguanine. These compounds are incorporated by HGPRT and kill the cells. Thus, 
culturing in the presence of either of these compounds will purge the population of 
any cell which have reverted to express the enzyme. 
3.1.1.2 Stages in Monoclonal Antibody Preparation 
The initial stage is to develop a screening assay for desired antibodies, and 
which could be adapted from existing methods. If no such information is available, 
immunization of the host animals to be used for fusion should proceed. The sample 
bleeds from these animals could be used to set up the novel screening assay and acted 
as a positive control in the assay. After a reliable screening assay has been 
established, the actual production of hybridomas can begin. Immunization is the first 
and most important step, its success determines the overall result of the experiment. 
If the immunized animals show good antibody response, then fusion can follow. 
Several days before fusion animals are injected with a sample of the same immunogen 
to induce the formation of desired antibody-secreting cells. Antibody-secreting cells 
are prepared from the immunized animal, mixed with the myeloma cells and fused 
by PEG. Finally, resulting hybrids are incubated in HAT selective medium and plated 
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in tissue culture multiwell dishes. Hybrid growth will be observed a week later. Since 
hybrids will secrete antibodies to its surrounding medium, hence, screening on the 
medium supernatant is required. Cells from positive wells are proliferated and single-
. � 
cell cloned. The procedures are rather time-consuming and cannot be interrupted. It 
seldom takes less than two months from start to end and may even take a year to 
finish (Harlow and Lane, 1988). It is reasonable to divide the production of 
monoclonal antibody into three main stages; they are screening assay development, 
mice immunization of mice and hybridoma preparation. 
3.1.1.2.1 Development of a Screening Assay 
A screening test should be able to identify the antibodies against the antigen. 
An ideal screening test should be rapid, easy to perform and able to handle large 
number of samples at one time. In principle, any assay capable to detect the antibody-
antigen reaction could be employed. For soluble antigens, the most popular and 
straight forward approaches are enzyme-linked immunosorbent assay (ELISA) (Voller 
et aL, 1979; Maggio，1980; Engvall, 1980) and solid-phase radioimmunoassay (Catt 
and Tregear, 1967; Tsu and Herzenberg, 1980). In these assays, the antigen of 
interest is immobilized to a solid support, then after subsequent addition of the test 
samples, anti-immunoglobulin antibody labelled with an enzyme (enzymes include 
peroxidase, alkaline phosphatase or jS-galactosidase) (in ELISA) or a radioisotope (in 
solid-phase radioimmunoassay, mostly radioactive iodine) and appropriate washing 
steps, the activities of either kind of labels will reflect the amount of related antibody 
in the test samples. The assay conditions, for example, reagent concentration, 
7 7 
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incubation time, must be optimised. The immunization could be done in animals 
(mice) which will be used as the spleen cell donor for fusion experiments. The 
antiserum obtained can be used to set up the assay. Since the amount of antiserum 
obtained from mice is limited, it is recommended that immunization is first done in 
rabbits, and the assay developed can be modified for the mouse model. 
Screening of hybridoma can also be carried out by immunofluorescence 
N 
(Ledbetter and Herzenberg, 1979) with a comparable sensitivity with ELISA and 
solid-phas6 radioimmunoassay. It is more suitable for cellular antigens. Assessment 
is done by visual observation using fluorescence microscope or by fluorescence-
activated cell sorter (Loken and Stall, 1982). Hybridoma supernatants containing 
complement-fixing antibodies against cell surface antigens may be detected by 
cytotoxicity assays. It is customary to use twostep assays in which antibody is bound 
to cells, unbound antibody is washed away, complement is added and the cells are 
examined for lysis. The assessment of lysis may be performed by using the trypan 
blue exclusion test or by staining with acridine orange and ethidium bromide (Lee et 
aL,l915; Parks et al” 1979). It could also be done by using 51Cr-release as a marker 
of cell death (McKearn, 1980). Cytotoxicity is somewhat cumbersome and has fallen 
from favour as a screening method unless cytotoxic antibodies are of interest. When 
an excess of anti-immunoglobulin or protein A-coated sheep red blood cells are 
centrifuged with immunoglobulin-coated lymphocytes, the red blood cells will adhere 
to the surface of the lymphocytes, forming rosettes. Resetting is a very sensitive and 
simple method of detection of cell-bound antibody (Parish and McKenzie, 1978; 
Sandrin et al., 1978) and the only equipment required is a centrifuge and a 
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microscope. Because most hybridoma cells grow at approximately the same rate, their 
II. . 
supernatants are usually ready to screen within a few days. All screening procedures 
must be fully developed and validated before fusion experiments begun, since there 
If'vi 
is no enough time to set up or refine the method after that. . 
• , . . 厂 . 
3.1.1.2.2 Mice Immunization 
Immunization in mice for monoclonal antibody production is the same as the 
procedures in polyclonal antisera production. Mice are immunized by monthly 
injection of a suitable dose of immunogen in Freund's adjuvants intraperitoneally. 
• . . 
Blood samples are obtained after immunization for the detection of antibody response 
by the screening assay previously developed. If the test is positive, this indicates that 
the host contains specific antibody-secreting cells ready for fusion. Fusion experiment 
would only be performed when the hosts are successfully immunized. Three to five 
days before fusion, the positive responder mice are given a final booster in a similar 
or higher dose (Stahli et al.，1980). This final booster is used to induce good, strong 
response and also to synchronize the maturation of the response. If this 
synchronization occurs, a large number of antigen specific antibody-secreting cells 
will appear in the local lymphoid tissues about 3 - 4 days later. This increases the 
relative concentration of the appropriate antibody-secreting cell as fusion partner. This 
final booster should be directed to the source of cells. The spleen normally is the best 
choice for B cells collection and therefore the booster should try to localize the 
response to the spleen. This could be done by an intravenous injection or if not 
possible, by. the intraperitoneal route. The immunogen solution should be prepared 
. . 7 9 
I in saline instead of Freund's adjuvants if the injection is done intravenously. 
I 
3.1.1.2.3 Hybridoma Production 
• 
Hybridoma production is the most important stage in monoclonal antibody 
preparation, and its success is dependent on the progress of the previous two stages 
• (Figure 3.2). A strong antibody response in hosts and the use of a good screening • 
method will make the production of hybridomas an easier task. For the fusion, 
antibody-secreting B cells are isolated from local lymphoid tissues, usually spleen, 
‘ .: / � . . '. ‘ , : . . . ‘ • 
and mixed with myeloma cells. The cell mixture is then centrifuged to generate good 
I 
cell-cell contact and fused with PEG. The fused cells are then removed from PEG 
• 
solution, diluted in HAT selective medium and plated in multiwell tissue culture 
dishes. After one to two weeks, samples of tissue culture medium supernatant are 
removed from wells with hybridoma growth and tested for the presence of desired 
antibodies by the screening method. Cells from positive wells are then proliferated 
and single-cell cloned. Final hybridoma cell lines secreting desired antibody could be 
established after re-screening on the cloned population. The cell lines should be 
frozen for indefinite preservation or proliferated in vitro or in vivo for antibody 
production. The antibody obtained should be characterised before its future use. 
Over the past decade, a number of variations in hybridization techniques have 
been evolved. Most of them are based on the techniques of Galfre et al. (1977) or 
Gefter et al (1977). The important variables in hybridization are concentration, 
purity, pH and duration of exposure of PEG. PEG concentration below 30 % hardly 
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Figure 3.2. General protocol for hybridoma production (Zola, 1987). 
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produces any hybridization, however, over 50 % toxicity becomes overwhelming. 
The optimal concentration of PEG was found to be 50 % (Galfre and Milstein, 1981). 
II 
The pH of the PEG solution have shown to affect the fusion frequency predominately 
(Sharon et al., 1980). Maximal numbers of hybridoma were obtained at pH 8.0 - 8.2. 
I: 
The fusion frequency, but also toxicity, increase with the time of exposure to PEG. 
Lower concentration of PEG (30 - 35 %) can be tolerated for longer time (7 minutes) 
than higher concentration (50 % for only 1 - 2 minutes) (Gefter et al•’ 1977). 
However, a high concentration (50 %) PEG and a short duration (1 minutes) PEG 
exposure protocol has been widely accepted because such protocol yields more 
specific antibody producing hybridoma (Lane, 1985). 
Some workers plate hybrid cells into normal complete tissue culture medium 
for one day before culturing the hybrids in HAT medium (Galfre and Milstein, 1981)， 
while many others plate them directly into selective medium (Zola and Brooks, 1982). 
However, there is no clear reason for a delay in HAT introduction and direct plating 
into HAT medium has now become a general practice. After a week in HAT 
medium, k is reasonable to assume that all the parental myeloma cells have been dead 
and any growing cells will be hybrids. At this point, HAT selection may be 
terminated. It is generally recommended that hybrids should be cultured in HT 
medium for a period before they are transferred to normal medium. This is because 
aminopterin is metabolized extremely slowly (Calabresi and Chabner, 1991) and it 
will persist in cells even after removal of HAT medium. If normal medium is used 
at this time, the hybrids will die due to the continuous inhibition of nucleic acids 
• 
synthesis by aminopterin without suitable compensation provided by the salvage 
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pathway (since both H and T are also removed). Zola and Brooks (1982) found that 
some hybrids died when taken out of HT medium, and suggested that the cells should 
be grown in HT medium permanently. It may be that the very slow catabolism of 
aminopterin, together with its extremely high persistence in cytoplasm, resulted in 
I 
unexpectedly slow recovery of the normal enzyme activity. The ingredients for HT 
medium are inexpensive and long-term growth in HT medium would provide little 
extra work, so permanent culturing in HT is highly recommended. 
I' 
Lymphoid cells often grow poorly or die when grown at low density. The 
reason is not well understood, but may be due to the requirement of some undefined 
growth factors. Hybrid cells also exhibit such density-dependent phenomena. This 
problem can be overcome by culturing together with a slow-growing or non-growing 
population of cells. Although the mechanism is not understood, these cells are usually 
termed as "feeders", implying that they make something needed for growth. 
Commonly used feeders include thymocytes (Lernhardt ^r al” 1978)，normal spleen 
cells (Galfre and Milstein, 1981) and peritoneal cells (Hengartner et al., 1978). 
An uncloned hybrid population is in fact a mixed population of desired 
antibody producing hybrids, non-producer hybrids, reverted myelomas and other cells 
I 
of the feeder layer. This heterogeneous cell mixture would be unstable and some 
antibody producing hybrids will be overgrown by other cell types and lost completely. 
In order to ensure the homogeneity of the hybrid population and the monoclonality 
of the antibody produced, it is essential to clone the positive secreting hybrids. In the 
work of Kohler and Milstein, they used soft agar culture to clone the anti-erythrocytes 
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antibody secreting hybrids. Cloning in soft agar has the disadvantage that colonies 
•pi. 
need to be plucked out and regrown in liquid culture prior to testing for antibody 
screening. Today, many workers prefer to clone by limiting dilution method 
I 
(Lefkovits and Waldemann, 1979). If cells are grown in small numbers, the fraction 
of wells with growth should follow the Poisson distribution: 
f(0) = e"x 
where f(0) is the fraction of wells with no growth and X is the average number of 
clones per well. If X = 1，then f(0) = 0.37. In order words, to obtain a reasonable 
•'... 
probability that wells with growth contain single clones, more than 37 % of wells 
should have no growth. Since the cloning efficiency will rarely be 100 %, practically, 
cells should be plated at 10，3 and 0.5 cells/well in a 96-well tissue culture plate. 
Cloning efficiency will be enhanced in the presence of feeders. The method requires 
a visual determination of single-cell derived colonies under a microscope, hence, it 
does not guarantee the clonality of the hybrids. Recloning, at least once, is thus 
highly recommended. 
3.1.2 Monoclonal Antibodies against 5a-estrane-3i8,17a-diol 
Monoclonal antibodies are developed against 5a-estrane-3jS, a-diol in this study 
which is divided into three parts, including (a) monoclonal antibody production, (b) 
I 
antibodies characterization and (c) the determination of 5a-estrane-3iS, 17a-diol in 
horse urine samples. The development of a suitable screening assay for specific anti-
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5of-estrane-3/3,17or-diol antibodies is essential for the subsequent steps in monoclonal 
antibody production. An ELISA, based on the rabbit polyclonal model explained in 
Chapter 2, will be developed for this purpose. Specific monoclonal antibodies to 
‘ . 
various steroids, such as testosterone (Kohen et al•，1982; Fantl and Wang, 1983), 
estradiol (de Lauzon et al, 1990), progestrone (White et al, 1982), Cortisol (Kis et 
al” 1982)，deoxycorticosterone (Al-Dujuili et al, 1984)，pregnanediol-3-glucuronide 
(Eshhar et al, 1981; Lewis et al, 1987) and aldosterone (de Lauzon et al, 1987)， 
have been previously produced, based on the method by Kohler and Milstein (1975). 
In this study, a method given by Zola (1987) was used with some modifications. The 
I ：  \ . t 
monoclonal antibodies developed are characterised in terms of their specificity and 
sensitivity to 5a-estrane-3j8，17a-diol. Suitable monoclonal antibodies are used to 
measure the urinary profile of 5a-estrane-3j8,17o;-diol of a gelding which has been 
administered with a proprietary preparation of nandrolone. The results are finally 
validated by comparing with results obtained from GC/MS. 
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3.2 Materials and Methods 
3.2.1 Reagents and Apparatus 
Tissue culture reagents included Dulbecco's modified Eagle's medium (high 
glucose; DME), Dulbecco's phosphate buffered saline (D-PBS), fetal bovine serum 
(FBS), trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA) solution, penicillin-
streptomycin, Fungizone, 8-azaguainine, sodium bicarbonate powder (NaHC03, tissue 
culture grade) and trypan blue solution (0.4 %) were purchased from Gibco 
Laboratories (Grand Island, NY, USA). Other tissue culture reagents included HAT 
supplement, HT supplement, polyethylene glycol (mol. wt. 1,300-1,600; PEG), red 
blood cells lysing buffer, dimethyl sulfoxide (DMSO) and L-glutamine (tissue culture 
tested) powder were supplied by Sigma (St, Louis, MO, USA). o-Phenylenediamine 
(OPD), anhydrous citric acid, goat anti-mouse Immunoglobulin G (IgG) (peroxidase 
labelled), Freund's complete and incomplete adjuvants (FCA, FIA), acetyl chloride, 
bovine serum albumin (fraction V; BSA), ovalbumin (grade V; OVA) and sheep 
serum albumin (fraction V; SSA) were also from Sigma. Tween 20, hydrogen 
peroxide (30 %), phosphate salts and. sodium chloride (all AR grade) were from E. 
Merck (Darmstadt, Germany). Methanol (HPLC grade), sulphuric acid (H2S04; 98 
%; AR grade), hydrochloric acid (HC1; 37 %; AR grade) and ether (AR grade) were 
supplied by Mallinckrodt (Paris, KN, USA). Pyridine was from Aldich (Milwaukee, 
WI, USA). Durabolin (nandrolone phenylpropionate) was the product of Organon 
(UK). MOX (2 % methoxyamine HC1 in pyridine) was purchased from Pierce 
(Rockford, IL, USA). Regisil (N,0-bis(trimethylsilyl)-trifIuoroacetamide and 10 % 
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trimethylsilyl chloride) was provided by Chrompack (Middelburg, The Netherlands). 
；,, 
All steroids used in the experiments were generously provided by Dr. Francis P.W. 
Tang of the Racing Laboratory, the Royal Hong Kong Jockey Club (RHKJC). 
I 
； ‘ . . 
All tissue culture wares were manufactured by Nunc (Rockilde, Denmark). 
ELISA microtitre plates (Microtest III) were purchased from Falcon (Oxnard, CA, 
USA). C18 Sep Pak cartridges were the products of Waters (Milford, MA, USA). 
3.2.2 Immunization of Mice with 5a-estrane-3j(3-ol-17-carboxymethyloxime-sheep 
serum albumin (EaSSA) 
5a-estrane-3jS-ol-17-carboxymethyloxime-sheep serum albumin (EaSSA) was 
synthesized as previously described (Chapter 2, section 2.2.2) and used as the 
immunogen in this study. EaSSA (1.4 mg) was mixed with physiological saline (0.85 
% w/v, 2 mL) and emulsified with Freund's adjuvant (2 mL) (complete adjuvant for 
initial immunization and incomplete adjuvant for other booster doses) as previously 
described (Chapter 2, section 2.2.3). Inbred male C57 mice (20 - 25 g) were supplied 
by the University Animal House and allowed access to food and water. A 12 hours 
dark and light cycle was maintained throughout the holding area. Totally, a group of 
ten mice was used for the experiment. Each mouse, received an injection of EaSSA 
(100 fig, 0.3 mL of the emulsion, intraperitoneal route). Similar booster doses 
prepared with FIA were given for the following three months at monthly interval. 
Mice which were tested to be positively immunized by ELISA, were given daily 
doses of EaSSA (200 iig in 0.85 % w/v saline, 0.3 mL) four days before the mice 
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were sacrificed. _,..:��... . I ‘ 
Blood samples from control mice and mice given EaSSA (on day 14 after 3rd 
booster) were collected. Three immunized mice were chosen randomly and were 
anaesthetized by ether. Blood (0.2 mL) was obtained by heart puncture with a 1 mL 
syringe (25 gauge size needle) and allowed to clot overnight at room temperature. 
Sera was obtained by centrifugation (3,000 r.p.m .，10 minutes). The samples were 
stored below -20�C for further analysis. The mice were allowed to recover for further 
studies. 
3.2.3 Hybridoma Preparation 
Methods described under this section, unless otherwise specified, were carried 
out in an aseptic atmosphere created by a laminar flow cabinet (SteriGARD Hood, 
Baker Company, Sanford, MI, USA). All the reagents (tissue culture media, fetal 
bovine serum) and apparatus (tissue culture wares, dissecting instruments, medium 
bottles, pipettes) were sterilized before use, either by the manufacturers or by 
autoclaving (121 °C, 20 minutes). The tissue culture reagents were warmed to 37°C 
before use. Cell densities of various cell suspensions were measured by Coulter 
Counter (Model ZM with sampling stand, Coulter Electronics, U.K.). Centrifugation 
of the cell suspensions was normally performed at 1,000 r.p.m. for 5 minutes. 
Incubation of cell cultures was in a humidified automatic carbon dioxide (0(¾) 
incubator (Forma Scientific, USA) at 37�C with an atmosphere of 5.0 % C02. 
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3.2.3.1 Preparation of Tissue Culture Working Solutions 
: 
_:::":::、:： . 
Fetal bovine serum (FBS), purchased commercially in sterilized form, was 
k 
heat inactivated at 56°C for 30 minutes before use, in order to inactivate serum 
1/.:. 
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reactive proteins (e.g. complements) which could damage the cells in culture. FBS 
was dispensed as 100 mL aliquots and stored at -20 °C prior to use 
. ‘ 
Dulbecco's modified Eagle's medium (DME) (4.5 mg/mL glucose) was used 
as the basic culture medium. Both DME and Dulbecco's phosphate buffered saline 
. ： . � • . •. 
(D-PBS) (0.01 M, pH 7.2) were obtained commercially in powder form. One litre of 
DME or D-PBS was prepared by dissolving a package of DME or D-PBS powder (1 
L) in double-distilled water (DD water) (700 mL). Sodium bicarbonate (NaHC03) 
(3.7 g, tissue culture grade) was added to the solution (no NaHC03 was added in case 
of D-PBS) until fully dissolved. The pH of the solution was adjusted to 7.1-7.2 by 
either hydrochloric acid (1 M) or sodium hydroxide solution (1 M). DD water was 
then added to bring the volume to one litre. The solution was then sterilized by 
negative pressure filtration through a 0.22 /xm pore size filter membrane. The 
sterilized solution was dispensed into 500 mL air-tight bottles and stored at4°C prior 
to use. 
Culture medium which contains serum, antibiotics and other essential 
components is referred as complete medium. It has a short shelf-life after mixing. 
Unless otherwise specified, all cells were cultured in complete DME (C-DME) 
medium. C-DME was prepared with heat inactivated FBS (10 %, v/v), antibiotics (50 
89 
units/mL penicillin, 50 fig/mL streptomycin and 2.5 jug/mL Fungizone) and L-
！ 
glutamine (300 /xg/mL) in DME. For example, to prepare a 100 mL solution of C-
DME, 10 mL heat inactivated FBS, 1 mL penicillin-streptomycin solution (stock 二 
100:1)，1 mL Fungizone solution (stock = 100:1) and 1 mL L-glutamine solution 
I 
(stock = 100:1) were mixed with 87 mL DME. C-DME was stored at 4 � C and C-
DME prepared over two weeks were discarded. 
Hybridoma selective medium (HAT medium) was prepared from C-DME, 
supplemented with sodium hypoxanthine (0.1 mM)，aminopterin (0.4 /xM) and 
thymidine (1.6 弘 M ) . This medium selectively allows the growth of successful fused 
hybrids. Hybridoma proliferation medium (HT medium), on the other hand, was 
prepared from, C-DME supplemented with sodium hypoxanthine (0.1 mM) and 
thymidine (1.6 /xM). HT medium supports the continuous growth of selected 
hybridoma after the withdrawal of aminopterin. The theory of the use of these two 
media is described in the section 3.1.1 in this chapter (Littlefield, 1964). The HAT 
or HT medium was prepared by dissolving 2 mL of the HAT or HT components 
solution (stock = 50:1) in 98 mL C-DME. Both media were stored at 4°C prior to 
use and discarded after two weeks. 
A freezing medium is used in cryopreservation of cell lines. It is made up in 
DME supplemented with heat inactivated FBS (20 %，v/v) and dimethyl sulfoxide (10 
%, v/v). The freezing medium was prepared by adding 10 mL heat-inactivated FBS 
and 5 mL dimethyl sulfoxide to 35 mL DME. Freezing medium was stored at 4°C 
and discarded after two weeks. 
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3.2.3.2 Cells Used in Fusion Experiments 
3.2.3.2.1 The Myeloma Cell Line (NS-1) 
. • 
The myeloma cell line used in the fusion experiments was known as 
P3/NSl/l-Ag4-l (NS-1) (American Type Cell Culture Collection number of TIB 18). 
The cell line was kindly provided by the Department of Anatomy, the Chinese 
University of Hong Kong (CUHK). NS-1 cells are resistant to 10-4 M 8-azaguainine 
and do not grow in HAT medium. The cell line have been used extensively in cell 
fusion experiments. The cells synthesizes K chains but do not secret free light chains. 
Intracellular k chains are only secreted in a hybrid cell when attached to heavy chains 
I 
(Kohler and Milstein, 1976). NS-1 was normally cultured in 25 mL canted neck tissue 
culture flasks with C-DME (5 mL) and incubated in the automatic C02 incubator. The 
cells were subcultured every three days while the cell monolayer became 90 % 
confluent. The old medium was removed by aspiration and the cell monolayer was 
washed with D-PBS (5 mL). The D-PBS was discarded and of trypsin-EDTA solution 
(0.05 % trypsin and 0.53 mM EDTA in D-PBS, 1 mL) (trypsinization) was added 
and incubated for 2 minutes at room temperature. Solution remained in the flask 
should be removed by aspiration and the flask was further incubated at 37°C for 10 
minutes in the automatic C02 incubator. C-DME (2 mL) was then added to stop 
trypsin-EDTA action. The cell monolayer was dissociated from the flask by 
mechanical shaking. After all the cells were detached, the cell suspension was 
transferred for further experiment or maintained at a cell density of 2-3 X 105 
cells/mL for further propagation. Due to mutation, HAT sensitive myeloma may 
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sometimes revert to cell that grow in HAT medium. The reverted cells would 
decrease the chance of growth for the successfully fused hybrid. In order to ensure 
the HAT sensitivity of NS-1 and as a precaution, the cells were cultured in the 
presence of 8-azaguainine (20 pg/mL) two weeks before fusion. The culture medium 
used was prepared by mixing 1 mL 8-azaguainine solution (stock = 10:1) with 9 mL 
C-DME. 
Two 25 mL flasks of NS-1 (for one fusion experiment) were subcultured on 
the day before fusion and maintained at the density of 2 - 3 x 105 cells/mL. On the 
day of fusion, an amount of 107 cells was obtained by trypsinization and resuspended 
in C-DME (5 mL). The cell viability of this cell suspension was determined by the 
trypan blue exclusion test (section 3.2.3.2.3) and was greater than 90 %. 
3.2.3.2.2 Preparation of Spleen Cells from Immunized Mice and Feeder Cells 
Mice immunized with EaSSA, tested to be anti-5a-estrane-3j(3，17a-diol IgG 
positive were used as spleen cells donors. The mice were given final booster doses 
EaSSA (200 iig in 0.85 % w/v saline, 0.3 mL) for four days just before fusion 
(Shibier et al.，1988). Each mouse was sacrificed by cervical dislocation and the 
whole body was washed with commercially available bleaching solution. The 
peritoneum was exposed by removing the covering skin. Ethanol (75 %, v/v) was 
then sprayed on the peritoneum. After the ethanol was evaporated, the spleen was 
dissected out aseptically into a 144 x 21 mm tissue culture petri dish containing C-
DME (15 mL). Spleen cells were released by injecting C-DME (10 mL) into the 
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spleen with a 25 gauge size needle connected syringe. This caused the spleen to swell 
and cells released (Zola, 1987). Using sterile forceps and syringe needle, spleen tissue 
was teased quickly, but gently, until there was no further release of cells upon teasing 
apart. The suspension was transferred to a 15 mL centrifuge tube allowing large 
clumps to settle for 5 minutes. The cell suspension was then transferred to another 
15 mL centrifuge tube for centrifugation (1,000 r.p.m., 5 minutes). The supernatant 
was discarded and the cell pellet was loosen. Red blood cells lysing buffer (1 mL) 
was added to remove all red cells. After incubation for 2 minutes at room 
temperature, D-PBS (10 mL) was added to stop the action of red blood cells lysing 
buffer and the cell suspension was then centrifuged (1,000 r.p.m., 5 minutes). A red 
blood cells free cell suspension was obtained by resuspending the cells with C-DME 
(5 mL). Normally, 5 - 7 X 107 cells (1 - 2 x 107 cells/mL) could be obtained by this 
method. • 
Feeder cells suspension was prepared similarly with an unimmunized mouse's 
spleen. However, the feeder cells were finally resuspended in HAT medium at a 
density of 2 x 106 cells/mL. The viabilities of these two cell suspensions were 
greater than 90 % in trypan blue exclusion test. 
3.2.3.2.3 Trypan Blue Exclusion Test 
The cell suspension (100 弘L) was mixed with trypan blue solution (0.4 %，100 
fjJL) in an eppendroff tube. After 3 - 5 minutes, the mixture was transferred to a 
haematocytometer and viewed under a light microscope (magnification = 200 x). 
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About a hundred cells were counted and the number of cells which stained blue was 
determined. The cell viability was calculated: 
100 - X 
Cell viability = X 100 % (X = no. of blue stained cells) 
100 
3.2.3.3 Somatic Cell Fusion Mediated by Polyethylene Glycol (PEG) 
The fusion procedure was modified from Zola's (1987) method. The spleen 
cell suspension from the mouse immunized with EaSSA was mixed with the NS-1 cell 
suspension in the ratio of 10:1. Spleen cell suspension of a total 7 x 107 cells was 
mixed with 7 x 106 NS-1 cells and incubated at 37°C for 30 minutes. The cell 
mixture was then centrifuged (1,000 r.p.m., 5 minutes) to give a pellet. The pellet 
was resuspended in a prewarmed solution of DME (1 mL, pH 8.0) containing PEG 
(50 % w/v) and incubated at 37°C for exactly 45 seconds, with gentle mixing (Lane, 
1985). DME (10 mL) was immediately added dropwise, with mixing, within 5 
minutes to quench the action of PEG. A further 5 mL of DME was added in the next 
5 minutes. This was followed by incubation at 37°C for 10 minutes and centrifugation 
(1,000 r.p.m., 5 minutes). Depending on the original amount of NS-1 cells mixed, 
the resulting hybrids were adjusted to the cell density of 4 x 105 cells/mL in HAT 
medium, e.g. if 7 x 106 NS-1 were used, 17.5 mL HAT medium was added. An 
equal volume of feeder cells suspension previously prepared, was mixed with the 
hybrid suspension. The cell mixture was then plated at a volume of 1 mL per well in 
24-well tissue culture plates and incubated at 37°C in a humidified C02 incubator. 
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3.2.3.4 Plate Maintenance 
After 7 days of incubation, the HAT medium was replaced with fresh HT 
medium (1 mL/well). Growth of hybrid colonies was visible microscopically after 
another 7 days of incubation (day 14 after fusion). The growth of hybrids will turn 
the colour of the medium to yellow due to the excretion of acidic metabolites. The 
medium was collected and replaced by fresh HT medium (1 mL/well). When a 
positive anti-5o!-estrane-3iS, 17a-diol antibody producer was identified, the cells were 
isolated and followed by cloning step. 
3.2.3.5 Screening of Hybridoma Supernatant for Anti-5Qf-estrane-3jS, 17of-diol 
Activity 
Specific anti-5a-estrane-3iS, 17a-diol antibodies produced by the hybrids were 
detected by an ELISA as described below (section 3.2.4). Supernatants from wells 
with hybrid colonial growth were collected and tested by ELISA. Positive wells were 
defined as those giving an absorbance approaching or greater than 0.5 in the assay. 
Wells which were negative twice were discarded. 
3.2.3.6 Cloning of the Positive Hybrids 
Positive antibodies producing hybrids must be cloned in order to ensure the 
monoclonality of the antibody produced and the homogenous growth of the 
hybridoma. The method of limiting dilution (Lefkovits and Waldemann, 1979) was 
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employed. Hybrid cells from positive wells were release from the bottom of the wells 
by pipetting the contents of the wells up and down for a dozen times. Hybrid cell 
suspension in HT medium of cell densities 100，30 and 10 cells/mL were prepared 
for cells from each positive well, e.g., positive hybrid suspension with a density 5 x 
105 cells/mL was first diluted to 5000 cells/mL by adding 100 \xL hybrid cell 
suspension to 10 mL HT medium. Then, 200 /xL of this suspension was dilution again 
in 10 mL HT medium, giving a 100 cells/mL suspension. Finally, 3.3 mL and 1 mL 
of 100 cells/mL suspension were mixed with 6.7 mL and 9 mL HT medium to give 
the other two cell densities, 30 cells/mL and 10 cells/mL, respectively. All dilutions 
were made in 15 mL centrifuge tubes. A feeder cells suspension (section 3.2.3.2.2) 
of cell density 2 x 105 cells/mL was also prepared in HT medium. A 96-well culture 
plate was divided into 4 columns for each of the cell density, with 100 ixL of cell 
suspension from each cell density was added to each well of the corresponding 
columns. An equal volume (100 fxL) of feeder cells suspension (2 x 105 cells/mL) 
was also added to each well. The plate was then incubated for 14 days. Microscopic 
observations were made for each well. Wells with more than one colony, 
asymmetrical colonies and those without hybrid growth were discarded. The 
supernatant of the remainder were screened again for specific anti-5a-estrane-3^, 17a-
diol antibodies by ELISA (section 3.2.4). 
3.2.3.7 Proliferation of Established Hybridoma 
Positive hybrids were allowed to increase cell mass and antibody production 
for further study. All the contents from a positive cloned well were transferred to a 
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larger well in a 24-well plate with C-DME (1 mL/weH) and incubated for a week. 
After cell growth showing 80 % confluent, the content was transferred to a 25 mL 
tissue culture flask in C-DME (5 mL). Subculturing of the cell was done every five 
days as previously described for NS-1 cells (section 3.2.3.2.1) without trypsinization. 
The old medium should be collected for further investigation. 
3.2.3.8 Cryopreservation of Myeloma and Established Hybridoma Cell Lines 
3.2.3.8.1 Freezing Cells 
Cryopreservation is necessary to preserve cell lines indefinitely. A 25 mL 
flask of NS-1 cells was prepared. An amount of 107 was obtained by subculturing step 
and the cell suspension was transferred to a 15 mL centrifuge tube. After 
centrifugation (1,000 r.p.m., 5 minutes), the cell density was adjusted to 5 x 106 
cells/mL by freezing medium at 4°C, e.g., 2 mL of freezing medium was added to 
107 cells to obtain a cell density of 5 x 106 cells/mL. The resulting cell suspension 
was dispensed into 1.8 mL freezing vials (1 mL/vial). The vials was then stored in 
a polystyrene box (1 cm thick) at -70°C overnight and the vials were transferred for 
storage in liquid nitrogen on the next day. The established hybridoma cell lines were 
also cryopreserved by the similar procedures. 
3.2.3.8,2 Thawing of Cells 
1 vial (1 ml) of frozen NS-1 cells or established hybridomas (cell density = 
5 x 106 cells/mL) was withdrawn from the liquid nitrogen and put immediately into 
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a 37°C water bath. After complete thawing, the content was transferred to a 15 mL 
centrifuge tube containing C-DME (10 mL). After centrifugation (1,000 r.p.m., 5 
minutes), the pellet was resuspended with C-DME (5 mL) and transferred to a 25 mL 
tissue culture flask for incubation. Growth of cell colonies became visible after a 
week. 
3.2.4 Enzyme-linked Immunosorbent Assay (ELISA) 
Mice antisera and all hybridoma supernatants were tested for specific anti-5a-
estrane-3j8,17a-diol IgG activity by ELISA as described previously in Chapter 2，with 
modifications. 
As shown in Figure 3.3, microtitre plates (Falcon Microtest III) were coated 
with 5a-estrane-3j8-ol-carboxymethyloxime-ovalbumin (EaOVA) or OVA (0.1 
mg/mL, 125 pL/well) in coating buffer (0.05 M phosphate buffer, pH 7.2) at 4 � C 
overnight in a humidified chamber. On the next day, the plates were washed three 
times with PBS-Tween (0.15 M phosphate buffer, pH 7.2, contains 0.9 % w/v 
sodium chloride and 0.05 % v/v Tween 20, freshly prepared) and shaken dry. All 
subsequent washes and all dilution of sera and antisera were done with PBS-Tween. 
The plate was then incubated at room temperature in a humidified chamber for one 
hour with each of the following reagents, with washing between each incubation: 
hybridoma supernatants or test serum (100 ^L/well) at the initial dilution of 1:100， 
serially (5-fold) diluted down columns, goat anti-mouse IgG labelled with peroxidase 
(100 /iL/well, 1:1000 dilution) and substrate solution (100 /xL/well, containing 0.1 
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Coat plates with 0.1 mg/mL 
EaOVA/OVA in coating 
buffer: 125 /xL/well 
… … 1 : : . ， ： : . | . . . . . . . . 
wash 3 times with 
PBS-Tween and shaken dry 
incubate with the test 
samples for 1 hour at 
room temperature 
i 
wash 3 times with 
PBS-Tween and shaken dry 
: . 1 . 
incubate with goat 
anti-mouse IgG 
peroxide labelled 
(1:1000): 100 /iL/well 
for 1 hour at room 
temperature 
I：；： ：  i 
wash 3 times with 
PBS-Tween and shaken dry 
i 
incubate with substrate 
solution: 100 /iL/well for 
20 mins. at room 
temperature 
i 
stop reaction by 
adding 25 % H2S04: 50 
/xL/well 
i 
read absorbance at 490 nm 
Figure 3.3. The schematic flow diagram of ELISA procedures for the 
detection of mouse anti-5a-estxane-3/3,17a-diol IgG activity. 
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% v/v hydrogen peroxide and 400 fzg/mL OPD in 0.15 M citrate-phosphate buffer, 
pH 5.0). The colour reaction was stopped after 20 minutes by the addition of H2S04 • 
(25 % v/v, 50 pL/well) and the absorbance at 490 nm was measured by a dual 
I 
wavelengths automatic microplate reader (Dyntech Laboratory model MR 710，USA) 
with the reference wavelength set at 630 nm. 
Antibody titres were calculated as the dilution of anti-serum giving an 
absorbance of 0.5. Anti-5a-estrane-3]8,17a-diol activity was defined as the antibody 
titre following coating with EaOVA where no activity was detected with unconjugated 
OVA. 
To determine the intra-assay coefficient, monoclonal antibody C1E7 (100 /xL, 
1:100 dilution) was added to each well of a EaOVA coated plate. The plate was then 
subjected to the ELISA procedures as described previously. Intra-assay coefficient 
was calculated as the coefficient of variation (standard derivation/mean x 100 %) 
between 96 wells on the plate. Four 96-well plates were set up with the same 
treatment and the interassay coefficient was calculation as the mean coefficient of 
variation between these plates. The two coefficients of C3D10 monoclonal antibody 
(1:5 dilution) were also determined by the similar method. 
3.2.5 Inhibition ELISA Analysis 
To confirm the specificity of the monoclonal antibodies developed against 5a-
estrane-3j8,17ce-diol, hapten inhibition studies similar to that described previously in 
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Chapter 2 was set up to detect any cross reactivity of the antibodies. 
Serial dilutions of various potential inhibitors were prepared. Aliquots (150 
liL) of each inhibitor were mixed with diluted hybridoma supernatants (150 fiL, 1:100 
for monoclonal antibody C1E7 and 1:5 for C3D10) in a glass test tube. The mixture 
was incubated overnight at 4°C. The supernatant (100 /xL) was assayed directly by 
ELISA. The inhibitors used include the 5o:-estrane-3iS, 17a-diol conjugated carrier 
proteins (5a-estrane-3/3- 17-carboxymethyloxime-bovine serum albumin (EaBSA), 
EaOVA and EaSSA), the unconjugated carrier protein (BSA, OVA and SSA), and 46 
other steroids listed in Table 2.1 (Chapter 2). A methanol control was used in the 
hapten inhibition studies, since all the steroids were initially dissolved in methanol. 
3.2.5.1 Calculation of Cross Reactivity 
Calculation of the cross reactivities of the monoclonal antibody, expressed as 
cross reactive percentage, CR %, was similar to that described in chapter 2 (section 
2.2.5.1). Briefly, the respective 50 % inhibition concentration (IC50) of each steroid 
was determined by interpolation of the inhibition curve. The CR % of each steroid 
is calculated as: 
IC50 of 5a-estrane-3/5,17of-diol 
CR % 二 ——X 100 % 
IC50 of the steroid 
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3.2.6 Interference of 5(10)-Estrene-3iS,naj-diol on the Recognition of 5of-Estrane-
3/5,17ce-diol by C1E7 Monoclonal Antibody 
This test was only performed on the C1E7 monoclonal antibody developed. 
It is to determine the effect of 5(10)-estrene-3]S, 17ce-diol on the recognition of 5a-
estrane-3i8，17a-diol by C1E7 monoclonal antibody. 
Serial dilutions (2-fold serially diluted from 20000 ng/mL) of 5(10)-estrene-
3i8,17ce-diol in PBS-Tween were prepared. Each concentration (150 pL) was mixed 
with C1E7 hybridoma supernatant (150 jxL, 1:50 dilution) in duplicate and incubated 
at 4°C overnight. The supernatant (100 /xL) was assayed directly by ELISA as 
described previously (section 3.2.4). Another similar experiment was set up. Serial 
dilution of 5(10)-estrene-3]S, 17a-diol (2-fold serially diluted from 30000 ng/mL) were 
prepared. Each concentration (150 pL) was mixed with C1E7 supernatant (100 fiL, 
1:33 dilution) and 5a-estrane-3j8,17a-diol (100 pL，30 ng/mL, working concentration 
10 ng/mL) in duplicate and incubated at 4°C overnight. The supernatant (100 fxL) 
was assayed directly by ELISA as described previously. It should be stated that the 
final working dilution of the hybridoma supernatant (1:100) and working 
concentrations of 5(10)-estrene-3j8，17a-diol remained the same in the two sets of 
experiments. 
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3.2.7 Administration of Proprietary Preparation of Nandrolone and Urine Samples 
Collection 
A 11-year-old thoroughbred gelding (450 kg) stabled at RHKJC, under 
standard conditions of feeding and exercise, was given an intramuscular dose of 
Durabolin (16 mL containing 400 mg nandrolone phenylpropionate in oily solution). 
Urine samples were collected from the horse before administration and then afterward 
daily for 19 days. The samples were stored at -20°C before further analysis. If 
�precipitation occurred when thawed out, the precipitate was discarded by 
centrifugation (3,000 r.p.m., 5 minutes). 
3.2.8 Quantification of 5a-Estrane-3j8,17a-diol in Urine Samples by ELISA Using 
Monoclonal Antibody C1E7 and the Comparison with GC/MS Analysis 
Urine samples were normally hydrolysed before analysis because 5a-estrane-
3j8，17o!-diol was present as glucuronide conjugate (Dumasia and Houghton, 1984). 
A new method of hydrolysis was employed which is known as methanolysis (Tang 
and Crone, 1989). This method can apparently release all steroids into free form in 
10 minutes without significant decomposition of the steroids. Besides hydrolysis, 
urine samples were derivatized by MOX and N,0-bis(trimethylsilyl)trifluoroacetamide 
(BSTFA) for GC/MS analysis (Tang and Crone, 1989). 
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3.2.8.1 Pretreatment of Urine Samples for ELISA Studies 
Urine samples (15 /iL), undiluted or diluted (10-fold in PBS-Tween), or 5a-
estrane-3/5,17a-diol standards (420, 210, 105，52.5, 26.25, 13.13, 6.7 and 0 ng/mL) 
in blank urine were dried under nitrogen (N2) at 60�C and methanolic hydrogen 
chloride (500 /xL, 78.5 g acetyl chloride in 1000 mL methanol, 1 M) was added to 
each tube and capped. The content was incubated at 60°C for 5 minutes and then 
dried under N2 at 60�C. The residue of each tube was reconstituted with 15 ixL PBS-
Tween for the use in hapten inhibition studies with ELISA method. 
3.2.8.2 Pretreatment of Urine Samples for GC/MS Analysis 
For confirmation studies by GC/MS, only urine samples collected on day 4 
and 12 after nandrolone administration were analyzed (sample code: AD4 and AD 12 
respectively). Duplicate sets of urine samples (5 mL) and duplicate sets of seven 
blank urine samples (5 mL each), containing of 0，50, 250，1000，2000 and 3000 ng 
5oj-estrane-3j8,17a-diol standard were applied to C18 cartridges which have been 
prewashed with methanol (10 mL per cartridge) and distilled water (10 mL per 
cartridge). Each cartridge was then washed with distilled water (5 mL) and eluted 
with methanol (5 mL) into to a Reacti vial. The content was dried under N2 at 60°C. 
Methanolic hydrogen chloride (1 M, 500 /iL) was added to each vial and capped. 
Incubation at 60�C was then followed for 5 minutes and then 500 ng of internal 
standard, 5(10)-estrene-3a, 17/5-diol, was added. The mixture was dried again under 
N2 at 60°C. MOX (40 /xL) was delivered to each vial which was then capped and 
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incubated at 60°C for 20 minutes. The solvent was then evaporated also at 60°C 
under N2 and Regisil (50 ^L) was added to each vial. Capped vials were incubated 
at 60°C for another 20 minutes 
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3.2.8.3 Quantification by ELISA 
The hydrolysed urine samples or standards (15 fiL) were transferred to a glass 
test tube and mixed with 135 fiL PBS-Tween buffer. C1E7 hybridoma supernatant 
(150 ixL, 1:100 dilution) was added to each tube, which were sealed and incubated 
at 4°C overnight. Aliquots (100 fiL) of the supernatant were assayed by ELISA as 
described previously (section 3.2.4). Another set of experiment was also performed 
on those non-hydrolysed samples or standards. From the data obtained, inhibition 
standard curves for 5aj-estrane-3jS, 17ce-diol were established and the level of 5a-
estrane-3/3,17a-diol in each samples were determined by matching the absorbance to 
the corresponding concentration on the inhibition standard curve. 
3.2.8.4 Quantification by GC/MS 
The GC/MS conditions were adapted from Tang and Crone (1989). All 
GC/MS analysis were performed using a gas chromatograph (model 3400，Varian, 
Sunnyvale, CA, USA) connected to an ion-trap detector (ITS40, Finnigan Mat, San 
Jose, CA, USA). The column (a cross-linked dimethyl silicone capillary; 12.5 m x 
0.2 mm i.d.; Ultra 1; Hewlett-Packard, Avondale, PA, USA) was initially at 150°C 
for 1 minute, then heated at 15°C per minute to a final temperature of 300�C and 
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held at 300°C for 5 minutes. Injections were splitless. Aliquots (1 ixL) of each 
pretreated urine samples or standards were analyzed by GC/MS. Quantification of5a-
estrane-3j8,17a-diol was performed by integration of the area of the peak 
corresponding to the ion 242 (relative to 330 from the internal standard). 
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3.3 Results 
3.3.1 Anti-5o:-estrane-3i8,17a-diol IgG Activity in Immunized Mice Sera 
Three mice were chosen randomly from the whole immunized population. All 
sera from those mice showed anti-5o:-estrane-3i8,17a-diol IgG activity with the 
antibody titres about 1 in 20,000 (Figure 3.4). No significant anti-OVA activity was 
detected. These mice remained alive for the fusion experiments. 
3.3.2 Hybrid Growth and Screening of Anti-5a-estrane-3j8，17a-diol Antibodies 
Those mice with positive anti-5a-estrane-3j8，17of-diol IgG response were 
sacrificed for three fusion experiments, A total of 68 wells were plated and 75 % of 
these wells showed hybrid growth. All wells were screened twice by ELISA. Finally, 
supernatants from three wells, namely A4, CI and C3, were showed to be positive 
in anti-5ce-estrane-3/3,17a-diol activity. These wells were isolated and followed by 
cloning. 
3.3.3 Cloning and Hybridoma Cell Lines Established 
Both hybrids from wells CI and C3 were cloned by the method of limiting 
dilution. Two clones, namely C1E7 and C3D10, which secrete monoclonal anti-5a-
estrane-3j3,17a-diol IgG, were successfully established. The antibody dilution curves 
for the monoclonal antibodies which secreted by these two clones, are shown in 
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Figure 3.4. Anti-5a-estrane-3j8,17a-diol antibody (IgG) activity in the sera taken 
on day 14th after the 3rd booster of EaSSA injection in mouse 1 (•) 
and mouse 2 (•)，as compared to preimmunization serum (x). Anti-
5o;-estrane-3iS, 17of-diol IgG activity was measured by ELISA. 
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Figure 3.5. Similarly, no significant anti-OVA activity has been detected. The 
supernatant from well A4 was lost the IgG activity after ten days of culturing. 
3.3.4 Characterization of C1E7 Monoclonal Antibody 
As shown in Figure 3.6, hapten inhibition studies with ELISA showed 
inhibition with 5ce-estrane-3]S,17a-diol conjugated proteins (EaBSA, EaOVA and 
EaSSA) when these were preincubated with the hybridoma supernatant. The carrier 
proteins (BSA, OVA and SSA) did not show any inhibition. The results confirmed 
the specificity of the reaction against 5a-estrane-3j8,17a-diol residues on the EaOVA. 
The antibody was found to cross react with three structurally similar steroids. 
They are, in the order of greatest response, 5a-estxane-3j8-ol-17-one, 5a-estrane-3/3-
ol-17-carboxymethyloxime (EaCMO) and 5o;-estrane-3/3,17a-diol (Figure 3.7). Both 
of them share a common backbone structure of 5a-estrane-3泠-ol. 
H 
5a-estrane-3]8-ol structure 
The inhibition curves of these steroids are showed in Figure 3.8 and their cross 
reactivities are listed in Table 3.2. It is obvious that the antibody has higher affinities 
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Figure 3.5. Anti-5a-estrane-3jS, 17a-diolantibody (IgG) activity in the supernatants 
C of hybridoma clones: C1E7 (•) and C3D10 (•)，as compared to 
supernatant of myeloma cell, NS-1 (x). Anti-5a-estrane-3^,Ha-diol 
IgG activity was measured by ELISA. 
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Figure 3.6. Inhibition ELISA of anti-5a-estrane-3jS, 17a-diol IgG activity after 
preincubation of hybridoma C1E7 supernatant (1:100 dilution) with 
various 
concentration of EaOVA (•)，EaSSA (•)，EaBSA (•) and 
OVA (x). Other carrier proteins (BSA, SSA) showed inhibition curves 
similar to that of OVA, which were omitted in this figure. 
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Figure 3.7. The structures of three strongly inhibiting steroids with C1E7 
monoclonal antibody in inhibition ELISA analysis. 
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Figure 3.8. Inhibition ELISA of anti-5a-estrane-3]S, 17a-diol IgG activity 
after preincubation of hybridoma C1E7 supernatant 
(1:100 
dilution) with various concentration of steroids: 5ce-estrane-3]S-
ol-17-one ( • ) ， E a C M O ( • ) ， 5 a - e s t r a n e - 3 / 3 , 1 7 a - d i o l ( • ) and 
methanol (x). 
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Table 3.2, Cross reactivities of anti-5ce-estrane-3jS,17aj-diol monoclonal antibody ！ 
C1E7 with various steroids. 
Cross Reacting Steroids : CR% 
5a-Estrane-3j8，17oKliol 100% 
5a-Estrane 等 ol-17-one 202% 
5ce-Estrane-3/3-ol-17-CMO 159% 




5a-Estrane- 17a-ol-3-one 4 .2% 
5a-Estrane-17i8-ol-3-one 5.4% 
5a-Estrane-3a-ol- 17-one 0.19% 
4-Estrene-3j8，17jS-diol 5.7% 
5(10)-Estrene-3,17-dione 5.3% 
5(10)-Estrene-3a, 17j8-diol 0.43% 
5(10)-Estrene-3]8, 17ce-diol 3.8% 
Nandrolone 4.1% 
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for 5a-estrane-3jS-ol-17-one and EaCMO than 5a-estrane-3jS,17a-diol. Moreover, the 
antibody exhibited a dose-response relationship to 5a-estrane-3^, 17a-diol within the 
concentration range 1 - 100 ng/mL. Other steroids with the cross reactivities of 
greater than 6 % are also listed in Table 3.2. The IC50 of these steroids were far in 
excess of 150 ng/mL which is 17-fold greater than that of 5a-estrane-3^,17a-diol. It 
should be noted that the parent drug, nandrolone, was also one of the inhibiting 
steroid. Figure 3.9 shows the inhibition curves of some of these steroids as compared 
with 5a-estrane-3j8,17a-diol. All other steroids, such as cortisone, estradiol, 
stanozolol, expressed their IC50 well outside the investigated concentration range. 
Their CR % were smaller than 0.01 % and were not considered as cross reacting 
species. 
3.3.5 Characterization of C3D10 Monoclonal Antibody 
Similar to C1E7, the ELISA reaction of C3D10 was not inhibited by 
preincubation with those carrier proteins (BSA, OVA and SSA). Only those 5a-
estrane-3/3,17a-diol conjugated proteins (EaBSA, EaOVA and EaSSA) inhibited the 
reaction after preincubation (Figure 3.10). 
This antibody cross reacted strongly with, in the order of greatest response, 
5a-estrane-3^,17a-diol, EaCMO, 5(10)-estrene-3a, 17^-diol, 4-estrene-3/3,17^-diol 
and 5af-estrane-3/3-ol-17-one (Figure 3.11). Their inhibition curves and cross 
reactivities are shown in Figure 3.12 and Table 3.3 respectively. Except for the fact 
that 5a-estrane-3i8,17a-diol, EaCMO and 5a-estrane-3/3-ol-17-one share a common 
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Figure 3.9. Inhibition ELISA of anti-5oj-estrane-3/?, 17or-diol IgG activity after 
� preincubation of hybridoma C1E7 supernatant (1:100 dilution) with 
nandrolone ( • ) and epiandrosterone (A), as compared to 5a-estrane-
3]S,17af-diol ( • ) and methanol (x). 
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Figure 3.10. Inhibition ELISA of anti-5a-estrane-3/3,17a-diol IgG activity after 
preincubation of hybridoma G3D10 supernatant (1:5 dilution) with 
various 
concentration of EaOVA (•)，EaSSA (•)，EaBSA (•) and 
OVA (X). Other carrier proteins (BSA, SSA) showed inhibition curves 
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5(10)-estrene-3a,17iS-diol 4-estrene-3/J,17^-diol 
Figure 3.11. The structures of five strongly inhibiting steroids with C3D10 
monoclonal antibody in inhibition ELISA analysis. 
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Figure 3.12. Inhibition ELISA of anti-5a-estrane-3/3,17a-diol IgG activity after 
一 preincubation of hybridoma C3D10 supernatant (1:5 dilution) with 
various concentration of steroids: 5a-estrane-3iS-ol-17-one (•), 
EaCMO(B), 5a-estrane-3j8,17a-diol ( • ) , 4-estrene-3/3,17^-diol (•), 
5(10)-estrene-3a, 17]8-diol ( • ) and methanol (X). 
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Table 3.3. Cross reactivities of anti-5a-estrane-3]8，17of-diol monoclonal antibody 
C3D10 with various steroids. 




5(10)-Estrene-3a, 17j8-diol 55.6% 
4-Estrene-3j8,17]S-diol 52.4% 
Other Cross Reacting Steroids : 









backbone 5a-estrane-3i8-ol structure, there is no common structure between the five 
cross reacting steroids. The affinity of this antibody is greatest for 5a-estrane-3/3，17a-
diol, however, the difference is not significant when comparing with other four 
steroids. In addition, the dose-response range for 5a-estrane-3/3,17a-diol to this 
antibody was 0.2 - 5 ^g/mL. Expected differentiation between estrane and estrene 
structures was not observed. Other steroids with a cross reactivity greater than 2 % 
are also listed in Table 3.3 and the CR % was limited between 5 - 25 %. Besides 
some of them are estrane or estrene compounds, no structural relationship could be 
made between these steroids. Cross reactivity smaller than 2 % could not be 
determined due to aqueous solubility problem. Most steroids precipitated out when 
their aqueous concentration exceeded 50 fig/mL. 
From the comparison of the two monoclonal antibodies, the specificity and 
sensitivity of C1E7 appears to be better than that of C3D10 in relation to the aim and 
subsequent studies were focused only on the C1E7 monoclonal antibody. 
3.3.6 Effect of 5(10)-Estrene-3jS, 17a-diol on the C1E7 Recognition of 5o;-Estrane-
3j8,17a-diol 
An important property of the monoclonal antibody is to discriminate 5a-
estrane-3j8,17a-diol from 5(lO)-estrene-30，17a-diol for accurate determination of the 
ratio between these two steroids. However, it was noted that the C1E7 monoclonal 
antibody exhibits a 3.8 % cross reaction with 5(10)-estrene-3/3,Ha-dioL This 
experiment was to test whether this slight cross reactivity would have any effect on 
121 
the antibody recognition. 
Figure 3.13 shows the inhibition curves for 5(10)-es1xene-3/3,17o;-dioL One 
of the curve shows the normal dose-response inhibition on ELISA. C1E7 recognized 
5(10)-estrene-3i8,17a-diol only when its concentration exceeded 100 ng/mL. The 
other curve was obtained by the same dose-response experimental treatment but in the 
presence of 10 ng/mL 5a-estrane-3]8,17a-diol. The results showed that the antibody 
could not recognize 5a-estrane-3/3,17a-diol (10 ng/mL) when the concentration of 
5(10)-estrene-3j8,17Q!-diol exceeded approximately 500 ng/mL. 
3.3.7 Quantification of 5a-Estrane-3j8,17a-diol in Urine Samples by ELISA Using 
Monoclonal Antibody C1E7 and the Comparison with GC/MS Analysis 
3.3.7.1 Urinary Profile of 5a-estrane-3jS, 17a-diol of a Nandrolone 
Administered Gelding 
The profile of 5a-estrane-3jS, 17a-diol of the horse urine established by ELISA 
is showed in Figure 3.14. No 5of-estrane-3j8,17a-diol was detected on the day of and 
the day before nandrolone administration by the assay. The peak concentration of the 
steroid was found in day 1 sample and maintained through day 2. Then the level 
dropped sharply to half of the peak value after day 4. Apparently constant rate of 
decrease in the steroid concentration was observed from day 5 to day 14. Thereafter, 
the 5a-estrane-3j8,17a-diol level remained almost constant and detectable to the end 
of the monitoring period. Moreover, there was no significant disagreement between 
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Figure 3.13. Inhibition ELISA of anti-5a-estrane-3i8，17a-diol IgG activity after 
preincubation of hybridoma C1E7 supernatant (1:100 dilution) with 
various concentration of 5(10)-estrene-3/5,17of-diol in the present (A) 
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Figure 3.14. Urinary 5a-estrane-3j8,17a-diol profile of a nandrolone administered 
gelding. The 5Qf-estxane-3/3,17a-diol concentration was determined by 
monoclonal antibody C1E7 based hapten inhibition studies with ELISA 
on hydrolysed ( • ) and non-hydrolysed (•) urine samples. 124 
hydrolysed and non-hydrolysed samples. 
3.3.7.2 Comparison with GC/MS Analysis 
By GC/MS, the concentration of 5o:-estrane-3i(3,17a-diol in urine sample AD4 
was 545 士 10 ng/mL and AD 12 was 135 土 5 ng/mL. By inhibition ELISA, the 
concentrations in AD4 and AD 12 were 559 土 15 ng/mL and 123 士 10 ng/mL after 
methanolysis or 526 士 13 ng/mL and 143 士 10 ng/mL without methanolysis 
respectively. 
3.3.9 Intra- and Inter-assay Coefficients 
The intra-assay coefficients of variation between 96-wells on the same plate 
for anti-5a-estrane-3/3,17of-diol IgG activity of monoclonal antibodies C1E7 (1:100 
dilution) and C3D10 (1:5 dilution) were 4.1 % and 5.6 %. The interassay variation, 
calculated as the average coefficient of variation between duplicate treatment on each 
of four separate plates, for monoclonal antibody C1E7 was 6.3 % and the interassay 
variation on three separate plates for monoclonal antibody C3D10 was 7.8 %. 
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3.4 Discussion 
Two monoclonal antibodies, C1E7 and C3D10, against 5o;-estrane-3/3,17ce-diol 
were produced in this study. An ELISA for the detection of these antibodies was 
established. As in previous studies with rabbits, three criteria were set out as the 
prerequisites for the specific identification of anti-5a-estrane-3jS, 17a-diol antibody: 
(a) IgG in the hybridoma supernatant binds to the immobilized EaOVA conjugate, but 
not to the immobilized unconjugated OVA, (b) Binding is inhibited by the 
preincubation of the hybridoma supernatant with steroid-protein conjugates (EaBSA, 
EaOVA and EaSSA), but not with the same unconjugated protein carriers, and (c) 
Binding is blocked by the preincubation of the hybridoma supernatant with the hapten 
5a-estrane-3iS, 17o:-diol alone, but not with other steroids (Yeung et al., 1985). The 
specificities of the monoclonal antibodies was determined by inhibition studies. Both 
antibodies did not show any cross reactivity to the carrier proteins. Inhibition was 
observed with 5a-estrane-3/5,17ce-diol conjugated proteins. These results further 
validated the ELISA reaction was determined by the specific binding between the 
antibodies and the 5a-estrane-30,17o:-diol residues on the immobilized EaOVA 
conjugate. However, the two monoclonal antibodies exhibited great difference in their 
cross reactivities and sensitivities to various steroid compounds. 
C1E7 reacted effectively with only three steroids, namely, 5a-estrane-3/3-ol-
17-one, EaCMO as well as 5a-estrane-3j8,Ha-dioL The epitope or the antigenic 
determinant is believed to be the 5a-estrane-3/3-ol structure. It should be noticed that 
the antibody has higher affinities to 5cx-estrane-3i8-ol- 17-one and EaCMO than 5a-
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estrane-3jS, 17a-diol. The explanation is that EaCMO is a residue on the immunogen 
EaSSA and 5a-estrane-3jS-ol-17-one is structurally different from EaCMO at C17 
position, at which a =N group in EaCMO is replaced by a = 0 group on 5a-estrane-
3j8-ol-17-one. The antibody is able to differentiate 5a-estrane-3/3,17ce-diol from its 
other two stereoisomers, 5a-estrane-3/3,17j8-diol and 5<x-estrane-3a, 17/3-diol. The 
differentiation of the 3a from the 3/3 isomer is expected since the 3a isomer has a 
different configuration from the antigenic determinant (5a-estrane-3/3-ol structure). 
The similar situation was observed in 5a-estrane-3a-ol- 17-one. However, the 
differentiation between the 17/? and the 17a isomers was rather unexpected. It has 
been suggested that the prime recognition site on the immunogen should be distal to 
the site of conjugation and the polyclonal antiserum produced would be insensitive to 
the change of this point (Niswender and Midgley, 1970; Spector and Parker, 1970; 
Bauminger et al., 1973). Insensitivity at this point could be accounted from the 
polyclonal activation of the host immune system which generated both 17a and 17/3 
specific antibodies (Burnet, 1968). This caused the polyclonal antiserum reacted 
equally well with 17a and 17/3 isomers (Chapter 2). This hypothesis could not be 
applied in our findings in which the configurational change at the point of conjugation 
(C17) greatly reduced the cross reactivity of the antibody. EaCMO is the residue of 
the immunogen, the antibody produced under its activation would be unique to its 
structure. EaCMO has a =N group at C17 position which forms a planar structure 
with the steroid D-ring (Wade, 1991). As a result, the antibody would strongly 
reacted with 5of-estrane-3jS-ol-17-one and EaCMO since both of them have a 5a-
estrane-3jS-ol as well as a D-ring-C17 planar structures. 5of-estrane-3]8,17ce-diol could 
only be considered as a cross-reacting (not totally good fitted) species because it 
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shares the common 5a-estrane-3j8-ol structure but lacks a D-ring-C17 planar 
structure. Hence, relative lower affinity was observed for this steroid. The case 
should also be applied to 5a-estrane-3/3,17jS-diol which also contains a 5a-estrane-3]0-
ol backbone. However, experimental results showed an unexpectedly high degree of 
reduction in the cross reaction. Stereoisomers with 0，/3 configuration possess a higher 
level of steric hindrance than those j8,of isomers in certain chemical reactions. 
(Taylor, 1987). It is likely that 5a-estrane-3]8,17j8-diol exerts steric repulsion force 
and expresses incompatibility with D-ring-C17 planar structure, which might be 
strong enough to partially oppose the binding force between the antibody and the 
steroid. Consequently, the cross reaction to 5a-estrane-3jS, 17/5-diol was observed to 
be relatively small in this study. The ability of this monoclonal antibody to 
discriminate 5a-estrane-3/3,17a-diol from other two stereoisomers attains the goal of 
the study. It appears that the antibody is able to differentiate the isomers in biological 
fluids. In addition to the specificity, the antibody recognizes 5a-estrane-30,17a-diol 
down to 1 ng/mL and follows a dose-response manner up to 100 ng/mL. The urinary 
5of-estrane-3jS, 17ce-diol level in nandrolone administered horses would fluctuate from 
10 to 1000 ng/mL (Houghton et aL , 1984) which are well within the sensitivity of the 
monoclonal antibody. 
The cross reactivity of C3D10 monoclonal antibody is rather unpredictable as 
it cross reacted strongly with 5o;-estrane-3i8,17a-diol, EaCMO, 5a-estxane-3/3-ol-17-
one, 4-estrene-3^,17iS-diol and 5(10)-estrene-3o:,17i8-diol (Figure 3.11). The former 
three steroids only shared the same backbone structure (5o;-estrane-3/3-ol), with no 
other structural connection. This antibody exhibited a higher affinity to 5a-estrane-
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3j8,17a-diol but the difference between other four was not significant. No conclusion 
could be drawn about the antigenic determinant of this antibody. In addition, the cross 
reactivities of C3D10 to other steroids were also exceptionally high and the pattern 
was irregular. The hybridoma secreting this antibody might be a descendant of an 
antibody producing cell with a broad steroid specificity which might be related to 
estrane and estrene structures. It should be noted that the cross reactivity of this 
antibody have not been entirely clarified due to the aqueous solubility of the steroids. 
Other tested steroids not listed as cross reacting species (Table 3.2) only represented 
their cross reactivities were smaller than 2 % • Their IC50 occurred beyond 50 /xg/mL, 
at which most steroids recrystallized and precipitated in the aqueous system. Hence, 
further evaluation on cross reactivity is not possible. 
As shown in Table 3.4, there is a general improvement in the sensitivity as 
well as specificity to 5a-estrane-3/3,17a-diol when a comparison is made between 
C1E7 monoclonal antibody and the polyclonal antibodies, 2-IB (Chapter 2). 
However, no such improvement or even weaker values are observed for C3D10 
monoclonal antibody. Previous studies showed that the specificities and sensitivities 
of monoclonal anti-steroid antibodies were not significantly improved when compared 
to polyclonal antiserum produced by conventional methods (Fantl and Wang, 1983; 
Al-Dujaili et al，1984). The production of the more specific and sensitive monoclonal 
antibody, C1E7, in this study would be depended on chance. It was suggested that 
more fusion experiments is necessary to established hybridomas which secrete 
monoclonal antibodies with better specificity and sensitivity characteristics (de Lauzon 
et al , 1990). Both polyclonal antiserum, 2-1B, and C3D10 monoclonal antibody are 
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Table 3.4. Comparison on the cross reactivities and sensitivity of anti-5a-estrane-
3j8,17a:-diol monclonal antibodies (C1E7 and C3D10) with polyclonal 
antiserum, 2-IB. 
C1E7 C3D10 2-1B 
Monclonal Monoclonal Polyclonal 
antibody antibody antiserum 
5a-Estrane-Steroids : CR % 
5a-Estrane-3j8,17a-diol 100% 100% 100% 
5a-Estrane-3]S-ol-17-one 202% 48.9% >100% 
5a-Estrane-3/5-ol-l1-CMO 159% 69.2% >100% 
5a-Estrane-3a,17/3-diol 0.66% 22.8% 42.6% 
5a-Estrane-3/3,17iS-diol 0.10% 7.6% 45.1% 
5a-Estrane-3a-ol-17-one 0.19% <2% 3.3% 
5ce-Estrane- 17a-ol-3-one 4.2% <2% 20.6% 
5a-Estrane-17j8-ol-3-one 5.4% 16.7% 16.6% 
Estrene-Steroids : 
5(10)-Estrene-3,17-dione 5.3% <2% 2.0% 
5(10)-Estrene-3a,17i8-diol 0.43% 55.6% 3.3% 
5(10)-Estrene-3]S, 17a-diol 3.8% <2% 5.8% 
4-Estrene-3]8,17i8-diol 5.7% 52.4% 22.8% 
Other Cross Reacting Steroids : 
5a-Androstane-3i8,17Q:-diol <0.01% 25.0% <1% 
5a-Dihydrotestosterone <0.01% 11.1% <1% 
Epiandrosterone 0.20% 14.3% 14.3% 
Nandrolone 4.1% 13.7% 10.5% 
Testosterone <0.01% 5.9% 2.7% 
Sensitivity in Inhibition ELISA 1 ng/mL 0.2 /xg/mL 0.1 ^g/mL 
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not suitable for quantifying 5a-estrane-3]8,17o!-diol in biological fluids with respect 
to the aim of this study which requires a specific and accurate measurement of the 
steroid. The abilities of both C3D10 monoclonal antibody and polyclonal antiserum, 
2-IB, to recognize 5a-estrane-3j8,17a-diol do not match the level of 5a-estrane-
3/3,17o:-ciiol in horse urine samples (lower level � 1 0 ng/mL). The inability of the 
polyclonal antiserum, 2-1B, to differentiate the stereoisomers of 5a-estrane-3/3，17a-
diol also precludes its use as a suitable antibody. In addition, the cross reaction of 
C3D10 monoclonal antibody with various steroids may lead to the presence of false 
positives in the assay. Moreover, the antibody titre in the C3D10 hybridoma 
supernatant is rather low (maximum absorbance ~ 0.6) which will lessen the 
resolution power and the sensitivity of the immunoassay. C1E7 appears to be better 
than others for measuring 5a-estrane-30,17a-diol. 
It was noted that C1E7 has 3.8 % cross reaction with 5(10)-estrene-3艮 17a-
diol. It have been tested that C1E7 will only react with 5(10)-estrene-3/3,17of-diol 
when the concentration of the steroid exceeds 100 ng/mL. The normal level of this 
steroid in colts' urine (if present) is around 20 - 30 ng/mL (information from RHKJC) 
which is not within the recognition range of C1E7. In addition, it was found that the 
recognition of 5a-estrane-3/3,17o:-diol (at its IC50) by C1E7 was abolished when 
5(10)-estrene-3j8,17a-diol concentration reached 500 ng/mL. Such a concentration 
would not be possible in horse urine under normal circumstance (information from 
RHKJC). 
Besides 5a-estrane-3jS, 17oi-diol, C1E7 also reacts effectively with EaCMO 
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(not a naturally occurring compound) and 5a-estrane-3/3-ol-17-one (with CR % = 159 
% and 201 % respectively). Like 5of-estrane-3jS, 17a-diol, 5a-estrane-3j8-ol- 17-one 
is also a urinary metabolite of nandrolone in horses but in a smaller amount 
(Houghton, 1977). It was found that the level of this steroid in nandrolone 
administered horses is at least 100-fold smaller than the concentration of 5a-estxane-
3jS,17a-diol (information from RHKJC), its contribution to the measurement of 5a-
estrane-3]S,17a-diol would be insignificant. The antibody was used to quantify the 
amount of 5a-estrane-3/3,17a-diol in a gelding administered with nandrolone, using 
inhibition ELISA method. The results match the amount quantified by GC/MS (within 
10 %). This suggests the antibody would be useful in detecting 5a-estrane-3^,17a-
diol in horse urine accurately. The 5a-estrane-3j8，17a-diol urinary profile in a 
nandrolone administered horse was established by this antibody. A similar nandrolone 
profile of the same urine samples using a commercial radioimmunoassay kit (Tang 
and Crone, 1989) showed the profiles agree with each other. It is also of interest that 
the antibody detects 5of-estrane-3j8,17o;-diol in both hydrolysed and non-hydrolysed 
samples, suggesting that the antibody is equally useful in detecting 5a-estrane-3/3，17a-
diol and its glucuronide conjugate. This could greatly simplify the present procedures 
by eliminating a hydrolysis step, making direct measurement on the samples possible. 
In summary, the hybridoma technique in this study produced two monoclonal 
antibodies against 5a-estrane-3/3,17a-diol which express different sensitivities to 5a-
estrane-3j8,17a-diol and cross reactivities to various steroids. One of which, C1E7, 
appeared to be a useful antibody for detecting and quantifying 5o:-estrane-3/3,17a-diol 
in horse urine samples. An hapten inhibition method by ELISA, was set up to 
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measure the concentration of 5a-estrane-3jS，17a-diol in urine samples of a nandrolone 
administered horse. When compared with GC/MS analysis, the immunoassay showed 
a similar sensitivity and accuracy. This monoclonal antibody may be used to develop 
immunoassays for the detection of 5a-estrane-3j8，17a-diol, hence providing another 
means of screening for nandrolone administration in geldings or fillies. Furthermore， 
after the completion of raising a monoclonal antibody to 5(10)-estrene-3^, 17a-diol, 
ELISAs used to determine the ratio between 5o;-estrane-3j8,17a-diol to 5(10)-estrene-
3/3，17a-diol would be possible. This will allow the mass screening of nandrolone 




Determination of 5a-estrane-3j8,17o;-diol to 5(10)-estrene-3/3,17a-diol ratio 
(estxane/estrene ratio) in colts' urine samples by gas chromatography/mass 
spectrometry (GC/MS) is the confirmatory method for nandrolone administration 
(Houghton et ah, 1985). The pretreatment procedures of this method are time-
consuming and complicated, not suitable for its use as a screening method. It has 
been suggested that a better system of detection would be an initial screening step 
with an immunoassay such as enzyme-linked immunosorbent assay (ELISA) and the 
positives are subsequently confirmed by GC/MS. To develop an ELISA for 
determination of estrane/estrene ratio, antibodies against the two steroids were raised. 
In this study, monoclonal antibodies against 5a-estrane-3jS,17oj-diol were 
developed for the detection of the steroid in horse urine samples by ELISA method. 
Two monoclonal antibodies, C1E7 and C3D10, have been successfully raised using 
standard hybridoma techniques (Zola, 1987). The monoclonal antibody, C1E7, is 
particularly useful for the detection of 5o;-estrane-3/3,17o;-dioL However, C1E7 is not 
an unique antibody specific to 5a-estrane-3/5,17of-diol. It cross reacts stronger with 
5af-estrane-3/3-ol-17-one and 5a-estrane-3jS-ol-17-carboxymethyloxime (EaCMO). 
These would be expected since the original immunogen (5of-estrane-30-ol-17-
carboxymethyloxime-sheep serum albumin (EaSSA)) possesses chemical structures 
that resemble more to both 5a-estrane-3j8-ol- 17-one and EaCMO. For the 
development of antibodies that is specific to steroids, the preparation of steroid-
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protein conjugate should allow a fuller expression of structural characteristics (Kohen 
et at., 1975; Corrie, 1979). The major characteristics of 5a-estrane-3jS，17a-diol 
structure would be the estrane rings, the hydro group at C5 position and the two 
hydroxyl groups at C3 and C17 positions. The point of conjugation should be avoided 
from masking of these structures. Conjugation at C6 position (de Lauzon et al，1990) 
or other positions would be suitable alternatives which could be difficult in practice 
because no reactive keto or hydroxyl group is available for conjugation at these 
positions. In addition, the sensitivity (1 ng/mL) of C1E7 monoclonal antibody in the 
ELISA is comparatively smaller than those monoclonal antibodies against other 
steroids, such as aldosterone (Hanquez et al., 1987) and pregnanediol-3-glucuronide 
(Lewis et al，1990), in similar ELISA systems. This would be the result of using the 
I. immunogen (EaSSA) which masks the full expression of 5a-estrane-3^, 17of-diol 
structural characteristics and thus decrease the sensitivity of the resulting antibody to 
5a-estrane-3j8,17a-diol. Nevertheless, the detection range of C1E7 with 5a-estrane-
3jS,17oj-diol was between 1 -100 ng/mL in the hapten inhibition analysis with ELISA 
which is sufficiently sensitive to detect the level of the steroid expected to be present 
in horse urine samples if nandrolone had been administered. 
Monoclonal antibody, C1E7, does not cross react with other steroids and with 
the cross reactivities not exceeding 6 %. The antibody discriminates 5a-estrane-
3j8,17of-diol from its stereoisomers (CR % < 1 %), which are only different from 
the configuration of 5a-estrane-3/3,17a-diol at the C3 and C17 positions. These 
isomers are minor urinary metabolites of nandrolone in horses (Houghton, 1977). The 
antibody also cross reacts with 5(10)-estrene-3]8,17of-diol (CR % = 3.8 %), however, 
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the level of 5(10)-estrene-3/5,17ce-diol in normal horse urine does not affect the 
recognition of the antibody to 5of-estrane-3j8, Ha-diol. Although the antibody also 
cross reacts with 5a-estrane-3i8-ol- 17-one and nandrolone, the ELISA method still 
achieved a comparable accuracy with GC/MS analysis in detecting the level of 5o；-
estrane-3/3,17a-diol in urine samples from a horse given with nandrolone. This 
suggests that C1E7 is a useful antibody for measuring 5a-estrane-3jS, 17o:-dioL An 
interesting finding in the study is that the antibody recognizes 5a-estrane-3/3,17o;-ciiol 
as well as its glucuronide. This may be helpful in the simplification of the procedures 
used and so direct measurement of total 5of-estrane-3i8,17a-diol in the urine samples 
would be possible. 
In this study, a polyclonal antiserum against 5a-estrane-3]8,17o;-diol was also 
developed. In the hapten inhibition analysis with ELISA using this antiserum, a high 
background absorbance ( - 0.2) was observed. Such phenomena would decrease the 
sensitivity of the ELISA and may be due to the non-specific binding between the thiol 
or disulphide groups on the ovalbumin of the coated steroid-protein conjugate with 
certain immunoglobulins in the antiserum (Samake et al” 1983; Mohammad et al, 
1983). Sulpher-free proteins such as casein or gelatin were suggested to be the carrier 
protein to avoid this interference (Hanquez et al., 1987). Nevertheless, this 
background interference was not observed in the ELISA using monoclonal antibodies. 
Previous studies have showed there is no obvious improvement in specificity as well 
as sensitivity of monoclonal antibodies against steroids when comparing with 
polyclonal antibodies (Fantl and Wang, 1983; Al-Dujaili et al” 1984). In this study, 
the anti-5a-estrane-3j8,17a-diol polyclonal antiserum, 2-1B, cross reacts with a larger 
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number of haptens, such as, nandrolone, 5a-estrane-3j8,17/3-diol and 5a-estrane-
3of,17/3-diol. In contrast, C1E7 monoclonal antibody exhibits an overall improvement 
in the pattern of cross reactivity as compared to 2-1B, especially with the two 
stereoisomers of 5a-estrane-3i8,17a-diol. In addition, the sensitivity was also 
improved with the monoclonal antibody (^g/mL in 2-IB to ng/mL in C1E7). 
However, another monoclonal antibody, C3D10, possesses weaker specificity than the 
polyclonal antiserum, 2-1B, and its sensitivity did not show any significant 
refinement. These results suggest that the specificity and sensitivity may not 
necessarily improve in monoclonal antibodies when compared with polyclonal 
antisera. The success of raising a suitable antibody only depends on chance. More 
fusion experiments is necessary in order to establish better hybridoma clones in terms 
of specificity and sensitivity. 
The ELISAs in this study gain comparable precision and reproducibility when 
their intra- and interassay coefficients are compared with those in other similar studies 
(Eshhar et al, 1981; Yeung et al,, 1985; Hanquez 过 al., 1987; Lewis et al, 1990). 
It is interesting to noted that both intra- and interassy coefficients of the ELISA using 
polyclonal antiserum were better than that of using monoclonal antibodies. 
The detection of nandrolone administration would be best studied by 
measuring the estrane/estrene ratio in colts' urine. This would be a more accurate and 
dependable parameter for the detection of nandrolone administration. The ELISA 
described in this study enables the accurate measurement of 5af-estrane-3^, 17o:-diol 
in urine samples by the C1E7 monoclonal antibody thus forming all important first 
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step in the detection of the estrane/estrene ratio. It would be expected that monoclonal 
antibodies to 5(10)-estrene-3jS，17a-diol could be raised, based on the method 
described in this study. The resulting ELISA methods using monoclonal antibodies 
against 5of-estrane-3iS, 17a-diol and 5(10)-estrene-3jS, 17a-diol would be a useful 
screening tool to detect colts，or other horse urine samples prior to confirmatory 
analysis by GC/MS, enabling the whole process to be simpler but more rapid and 
cost-effective. 
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